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ABSTRACT
Inhibition of dihydrofolic reductase in the rat 
liver by the folic acid antagonist methotrexate, 
amethopterin, is followed by a rapid recovery of enzyme 
activity. During serial administration of the 
antimetabolite, dihydrofolic reductase - methotrexate 
complexes were shown to be stable to dissociation, and 
methotrexate was readily accessible at all times to the 
enzyme. Antifolate treatment induced the synthesis of a 
dihydrofolic reductase that was present in small amounts 
in the livers of untreated rats. Two reductases, which 
were present in approximately equal amounts in some liver 
extracts from methotrexate-treated rats, were purified by 
a combination of ammonium sulphate fractionation and 
chromatography on Sephadex G-100. The molecular weights 
of the enzymes were estimated to be 20,000 - 500 and 
24,500 - 500 respectively for the main reductase 
component present in the normal rat liver and for the 
enzyme synthesised in the presence of methotrexate. The 
two dihydrofolic reductase enzymes migrated in opposite 
directions when subjected to electrophoresis on cellulose 
acetate strips at pH 8.5, but were shown to have similar 
Michaelis constants for dihydrofolate at pH 7.4. pH 
curves had similar profiles for the two enzymes. Evidence 
was found that the synthesis of dihydrofolic reductase in 
the presence of methotrexate involved an enzyme which
exhibited some degree of reversibility in its binding of 
the antifolate. The adaptation of the liver in relation 
to mechanisms for drug resistaince during methotrexate 
therapy is discussed.
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A. INTRODUCTION
1. DIHYDROFOLIC REDUCTASE
(I) Action of dihydrofolic reductase
Dihydrofolic reductase catalyses the reduction of 
dihydrofolate (FH ) (equation 1) and sometimes folate 
(F) (equation 2) to the co-enzymic form, 5,6,7,8- 
tetrahydrofolate (FH^) (Zakrzewski and Nichol, 1960).
FHg + NADPH + ^ PH^ + NADP"^ (equation 1)
F + 2NADPH + 2H‘^-- ^FH^ + 2NADP"^ (equation 2)
It is closely associated with thymidylate synthetase
as it replenishes FH. from the FH_.that is formed as a ^ 4 2
byproduct in the reaction catalysed by the above enzyme 
during the reductive méthylation of deoxyuridylate (d UMP) 
to thymidylate (d TMP) (equation 3) (Friedkin, 1963).
N^, N^°-methylene-FH^ + d UMP FH^ + d TMP
(equation 3).
As folate reductases catalyse a more rapid NADPH 
reduction of FH^ than F (Peters and Greenberg, 1958, 1959),
the term dihydrofolic reductase is preferred. The enzyme
has the systemmatic name 5,6,7,8-tetrahydrofolate NAD(P) 
oxidoreductase (EC 1.5.1.3).
The conversion of F and FH^ takes place in two steps ; 
firstly the NADPH-dependent reduction of F to 7,8-FH^ and
i l* . ,JÜ
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secondly the NADPH or NADH-dependent reduction of FH^ 
to FH^. Folate reducing enzymes isolated from animal 
tissues suggest that both these reactions are mediated
9
by the same enzyme (Zakrzewski and Nichol, 1960;
Mathews and Huennekens, 1963; Morales and Greenberg,
1964; Bertino et al. , 1965b; Kaufman and Gardner, 1966 ; 
Zakrzewski et al. , 1966 ; Perkins et al. , 1967). However, 
Noronha and Sreenivasan (1960) working with rat liver, 
were able to separate the two reductive steps. The 
observation by Condit and Mead (1963) that the conversion 
of FH^ to the liver citrovorum factor (N^-formyl-FH^) and 
related compounds is unaffected by the folic acid 
'antagonist, methotrexate, (MTX) while the conversion of 
folic acid is inhibited under these conditions, again 
suggests that two different enzymes are involved.
Albrecht and Hutchison (1968) have shown that the 
tetrahydrofolate-forming system of the amethopterin­
sensitive strain of S. faecium var. durans consists of 
two enzymes. One species of dihydrofolic reductase is 
specific for FH^, while the other enzyme catalyses both 
the reduction of F and FH_.
The reductions of F and FH^ to FH^ are inhibited, 
in those species examined, by the diamino derivatives of 
folate, pteridines, purines and pyrimidines (Zakrzewski 
1963 ; Wang and Werkheiser, 1964; Hitchings and Burchall, 
1965).
D
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(II) The significance of dihydrofolic reductase activity
in folic acid metabolism
Dihydrofolic reductase activity has been shown by
many workers to be of great importance, since complete
suppression of its activity prevents many of the coenzymic
%
activities of F, especially those involved in thymine 
synthesis (Totter, 1955 ; Balls and Danois, 1955; Sartorelli 
and Booth, 1961, 1962). The immediate effect of inhibition 
of dihydrofolic reductase is the decrease in the 
concentration of FH^ and its derivatives in the cell 
(Hakala, 1957; Hakala and Taylor, 1959 ; Hakala et al. , 
1961). That the reduced derivatives of F are the active 
form of the vitamin is indicated by the observation that 
concomitantly administered foli'nic acid, N^-f ormyl-FH^, 
will reverse the toxic effects in mice of aminopterin and 
MTX, potent inhibitors of dihydrofolic reductase, while F 
affords no such protection (Nichol and Welch, 1950; 
Greenspan et al. , 1950 ; Mead et al., 1961a; Goldin et al. , 
1953a, b, 1955b).
Several tetrahydrofolate derivatives are involved 
in the transfer of 1-carbon groups in a number of essential 
reactions in the biosynthetic pathways of nucleic acids and 
proteins. These include the interconversions of serine and 
glycine (Lascelles and Woods, 1954; Lascelles et al., 1954; 
Totter et al., 1949 ; Elwyn and Sprinson, 1950), the
- 9 -
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hydroxylation of phenylalanine to tyrosine (Goodfriend,
1960)5 and the production of methionine from homocysteine 
(Larrabee et al., 1961).
The donation of a formyl group to methionyl-transfer 
RNA is important (Dickerman et al., 1967), as it is an 
initiator in polypeptide chain synthesis (Eisenstadt and 
Lengyel, 1966). derivatives are also involved in the
catabolism of purines (Rabinowitz and Pricer, 1956a, b, c), 
and L-histidine (Miller and Waelsch, 1957; Tabor and 
Rabinowitz, 1956).
Loss of dihydrofolic reductase activity has its main effect 
on the formation of the purine ring, and the methyl group 
of the pyrimidine, thymine. The , N^^-anhydro formyl 
derivative of FH^ is required for the transfer of formyl 
groups into the 8 and 2 positions of the purine ring in 
the reactions respectively of glycineamide ribonucleotide 
(GAR) to formylglycineamide ribonucleotide (FGAR), and of 
5-amino-4-imidazole carboxamide ribonucleotide (AICAR) to 
formyl 5-amino-4-imidazole carboxamide ribonucleotide 
(FAICAR) (Greenberg, 1951, 1954; Flaks et al., 1957;
Schulman and Buchanan, 1952). In thymidylate synthesis the 
, N^^-methylene derivative is required for the méthylation 
of deoxyuridylate to thymidylate (Friedkin and Roberts, 1956 ; 
Reichard, 1955).
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The 1-carbon moieties of the FH^-derivatives are 
either formed de novo by neogenesis of methyl groups 
(Bregoff and Delwiche, 1955) or are derived from the 
metabolism of several eumino acids, such as methionine, 
glycine and serine (Stekol, 1955). Choline also has such 
"labile" methyl groups (du Vignaud et al., 1950a, b;
Sakami and Welch, 1950). The folate coenzymes are in 
equilibrium by enzyme-mediated reactions (figure 1), such 
that the removal of the 1-carbon moiety of 5,10-methylene 
FH^ by hydroxylamine (Osborne et al., 1960) results in 
depletion of the intracellular pool of 1-carbon adducts, 
and also 10-formyl FH^. This will in turn inhibit peptide 
chain initiation (Nixon and Bertino, 1970).
•Tumour cells, which divide rapidly, have elevated 
levels of both dihydrofolic reductase, and the 
tetrahydrofolate-dependent enzymes. In leukaemic leukocytes 
the former enzyme reaches a level as much as thirty times 
that found in normal leukocytes (Bertino et al., 1963b), 
while the levels of the FH^-dependent enzymes only have a 
two-fold increase. It would appear as though the reaction 
mediated by dihydrofolic reductase is rate limiting for all 
the subsequent steps in the metabolism of 1-carbon units(figure 2)
(111) Distribution-of dihydrofolic reductase in vertebrate 
tissues. insects and micro-organisms_________________
Dihydrofolic reductase activity is readily detectable
— 13 —
in the liver, kidney, thymus, intestinal mucosa and 
spleen from the rat, rabbit, guinea pig, hamster and 
mouse (Roberts and Hall, 1963). Very small amounts 
of the enzyme are present in the lung, heart and brain 
of all species examined. Human tissues have low levels 
of dihydrofolic reductase, which has nevertheless been 
shown to be present in the liver, gastric mucosa, 
placenta, in some specimens of normal skin, in psoriotic 
epidermis, and in stimulated bone marrow (Tonato et al., 
1967; Grignani et al., 1967). It is present in the 
leukocytes from normal patients, and in those patients 
with chronic lymphatic leukaemia, acute leukaemia and 
chronic myelogenous leukaemia (Tonato et al., 1967;
Bertino et al. , 1960, 1963 ; Wilmanns, 1962; Roberts and 
Hall, 1964, 1967).
In rat tissues the liver had the highest content 
(Braganea and Kenkare, 1964). The kidney had about 70% 
of the dihydrofolic reductase content of the liver, while 
none could be detected in the muscle or lung.
The rabbit spleen had the highest ability to reduce 
folate (1.66 m[i moles of MTX binding sites per g of tissue) 
(Roberts and Hall, 1963). The liver and spleen of cat, 
liver of sheep and kidney of dog contain 0.1 mfj, moles or 
more per g of tissue. Mouse and rat liver contained 150 
to 300 times more enzyme per g of tissue than human placenta
- 14 -
or liver (Jarabak and Bachur, 1970).
Embryonic tissues have a relatively high content of 
dihydrofolic reductase. It appears highest at the earlier 
stages of development in the chick embryo and human foetus 
(Silver et al., 1962; Roberts and Hall, 1965). Foetal 
liver tissues have a particularly high content (Roberts 
and Hall, 1965), but dihydrofolic reductase levels are not 
elevated in regenerating liver (Braganea and Kenkare, 1964; 
Brown et al., 1965a; Ngu et al., 1964; Hillcoat, 1965), 
although large increases in the level of thymidylate 
synthetase have been reported. Beltz (1962), however, 
concluded from X-ray irradiation studies that thymidylate 
synthetase activity after partial hepatectomy was not 
rate-limiting to DNA synthesis.
Brown et al. (1965b) and Wang et al. (1967) showed
that most of the dihydrofolic reductase was found 
intracellularly in the cytoplasm and the microsomal 
fraction. Wang et al. (1967) could detect no reductase 
activity in the mitochondria upon rupture by sonication, 
while Brown et al. ( 1965b) shov/ed that 12% of their enzyme 
was released from the mitochondria by deoxycholate.
Noronha and Sreenivasan (1960) found that folic reductase 
activity in the rat liver was localised in the supernatant 
fraction of the homogenate, while dihydrofolic reductase
- 15 -
activity was associated with the mitochondria.
Enzymes resembling the dihydrofolic reductase of 
vertebrate tissues have been found in Streptococcus 
faecalis (Blakley and McDougall, 1961; Albrecht et al.,
1966; Hillcoat and Blakley, ^1966 ; Nixon and Blakley,
1968), Escherichia coli (Mathews and Sutherland, 1965 ; 
Burchell and Hitchings, 1964, 1965), Diplococcus pneumoniae 
(Sirotnak and Hutchison, 1966 ; Sirotnak et al., 1964a, b), 
Lactobacillus leichmanii (Kessel and Roberts, 1965), 
Staphylococcus aureus (Burchell and Hitchings, 1964, 1965), 
and in Proteus vulgaris (Burchall and Hitchings, 1964,
1965). This enzyme has been isolated from trypanosomes 
(Jaffe and McCormack, 1967), yeasts (Bush and Donaldson,
1965) and from insects, (Grzelakowska-Sztabert and Zielinka, 
1967).
(IV) Purification and some properties of dihydrofolic 
reductase__________________________________________
Dihydrofolic reductase from chicken liver was the
first such enzyme to be partially purified and studied
(Futterman and Silverman, 1957 ; Zakrzewski and Nichol, 1958;
Zakrzewski, 1960a, b ; Osborn and Huennekens, 1958). An
8000-fold purification has been obtained by protamine
sulphate treatment, ammonium sulphate precipitation, gel
filtration on Sephadex G-75, followed by chromatography on
- 16 -
hydroxylapatite, carboxymethylcellulose and DEAE cellulose 
(Kaufman and Gardiner, 1965, 1966). The specific activity 
of the pure enzyme is 14 - 15 p moles FH^ reduced / min /* 
mg protein. The turnover number in 300 - 350 moles per 
min / mole of enzyme at pH 7.4, which is similar to that 
of the calf thymus reductase (Nath and Greenberg, 1962; 
Greenberg et al., 1966), while the turnover number obtained 
for human placental enzyme by Jarabak and Bachur (1971) is 
518. The turnover number of the chicken liver enzyme is 
3 - 4  times higher at pH 4.0.
The chicken liver enzyme has a molecular weight in 
the region of 21,000 to 24,000 as indicated by sucrose 
gradient ultra-centrifugation and sedimentation equilibrium 
studies (Kaufman, 1964 ; Kaufman and Gardiner, 1965, 1966), 
and has been obtained for the enzyme isolated from Sarcoma- 
180 (AT/3000) cells by Sephadex G-100 chromatography 
(Zakrzewski et ah, 1966), and estimated to be 21,000.
The absorption spectrum for pure chicken liver 
enzyme has a maximum at 278 with a slight shoulder at
282 m|t, and a distinct shoulder at 290 m[i indicating 
significant amounts of tryptophan (Kaufman and Gardiner,
1966).
Folate is preferentially used as a substrate at low 
pH values, so that the K^ for the Sarcoma-180 (AT/3000)cell
MI — 17 —
extract for folate increased from 1.8 x 10 at pH
4.0 to 4 X 10"^M at pH 6.0 (Hakala et al. , 1961;
Zakrzewski et al. , 1966), where when v = -^ ;
V is the velocity of appearance' of product or disappearance
of substrate at a given substrate concentration , and V
is the velocity when enzyme is saturated with substrate.
Other K values for folate have been obtained; for example m ^
7.4 X 10"^M (Bertino et al., 1964) for the Ehrlich ascites 
cell enzyme, which is similar to the value obtained by 
Zakrzewski (1960a).
The value for FH^ appears to remain constant over 
a pH range. Bertino et al. (1964) obtained values of 1.5 x 10
and l.SxlO'^M at pH 5.9 and pH 7.5 respectively for the Ehrlich 
ascites enzyme, while the Sarcoma-180 enzyme has a value of
6.1 X lO'^M over a pH range. Jarabak and Bachur (1971) when 
comparing the human placental dihydrofolic reductase with
that of the rat and the mouse liver obtained values of 1.1 x
- 7 - 710 M for the human enzyme, and 1.0 x 10 M for both the rat
and the mouse reductase. The K for FH_ for normal andm 2
leukaemic leukocytes is 1 x 10 (Bertino et al., 1960,
1963b).
K values of 2.6 x lO'^M and 5.6 x 10~^M have been m
obtained for NADH and NADPH respectively for the Ehrlich 
ascites and the L1210 murine lymphoma dihydrofolic 
reductases (Bertino et al., 1964, 1965; Perkins et al., 1967).
TZ]
—  18 —
NADP is a competitive inhibitor of dihydrofolic reductase 
for chicken liver and Ehrlich ascites enzyme with respect 
to NADPH. values obtained were 2.4 x 10”^M and 4.9 x
10 respectively for the two enz^nnes.
There are two pH optima for chicken liver enzyme 
using NADPH and FH^ as substrates; a major one at pH 4.0 
and a minor one at pH 7.2 to 7.5 (Kaufman, 1964; Kaufman 
and Gardiner, 1965). There is, however, only one pH optimum 
between pH 3.5 and 5.5 when the substrate pairs of folate 
and NADPH, FH^ and NADH and folate and NADH are used. Some, 
but not all dihydrofolic reductases from other vertebrate 
tissues show double pH optima. The pH optimum for FH^ for 
the enzyme in normal and leukaemic leukocytes is between 
8.3 and 8.4, with a smaller optimum near pH 5.0 (Bertino et 
al., 1963b).
(V) Activation of dihydrofolic reductase by salts, urea, 
mercurials and other agents
Activation of dihydrofolic reductase by salts has 
been observed for the enzyme isolated from chicken liver 
(Kaufman, 1963), guinea pig liver (Bertino, 1962), mouse 
leukaemic cells (Schrecker and Huennekens, 1964 ; Reyes and 
Huennekens, 1967 ; Bertino, 1962), Ehrlich ascites carcinoma 
cells (Bertino et a 1.' , 1965b ; Bertino, 1962 ; Perkins and 
Bertino, 1964), and-from patients with chronic granulocytic 
and acute leukaemia (Bertino, 1962).
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Bertino (1962) thought that the activation of
dihydrofolic reductase which is most marked with the
++ ++ ++ chlorides of Ba , Mn and Ca between pH 5.0 and 7.0
with either folate or FH^ as the substrate, was due to
the cation. However, Reyes and Huennekens (1967) showed
that the activation is a function of both the anion and
the cation, because the activation versus concentration
curves obtained with BaCl^ and CaCl^ differed from those
for the chlorides of Li^, Na*^, , Rb^, Cs^ and. NH.**".
Organic mercurial compounds in concentrations of 
10 ^ - 10 produce striking activation of chicken liver 
(Kaufman, 1963, 1964) and Ehrlich ascites carcinoma cell 
(Perkins and Bertino, 1964, 1965) dihydrofolic reductases, 
which can be reversed on removal of the bound mercurial by 
thiols (Perkins and Bertino, 1965).
Iodine will activate chicken liver enzyme (Kaufman,
1966) presumably by combining with a sulphydryl group on 
the enzyme with the formation of a sulphenyl iodide (equation
4 ) .
ESH + 2Iç==^ESl + + I” (equation 4).
This activation is reversed by mercaptoethanol, so that the 
enzyme regained has the same properties as the original 
preparation and can be activated again by iodine.
In the presence of urea, salts or guanidine, 5,5*-
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dithiobis-(2-nitrobenzoic acid) (DTNB) will activate the
dihydrofolic reductase from the L1210 lymphoma (Reyes and
Huennekens, 1967). Urea,salts or guanidine presumably
make more thiol groups accessible to DTNB, which will also
stabilise the enzyme in this active configuration.
»
It is thought that all these agents activate 
dihydrofolic reductase by producing a change in the 
configuration of the enzyme that is catalytically favourable 
(Kaufman, 1964; Perkins and Bertino, 1965).
(VI) Multiple forms of dihydrofolic reductase
Multiple forms of the enzyme have been detected by 
column chromatography (Kaufman and Gardiner, 1966; Sirotnak 
and Hutchison, 1967; Perkins et al., 1967), by filtration 
through Sephadex (Hillcoat and Blakley, 1966; Sirotnak and 
Hutchison, 1966), and by electrophoresis on starch gel 
(Mell et al., 1968). Separation of the two main enzyme 
peaks of chicken liver dihydrofolic reductase on starch gel 
or by DEAE-Sephadex chromatography, and subsequent 
characterization revealed that one enzyme form was activated 
to a lesser degree by PCMB, and small differences in their 
sensitivity to amethopterin were detected (Mell et al., 1968)
Dihydrofolic reductases have been purified from the 
parent SF/0 strain of S. faecalis (Blakley and McDougall, 
1961; Albrecht et al., 1966; Hillcoat and Blakley, 1966),
-  21 -
and from two MTX-resistant strains, SF/A and SF/A 
(Albrecht et al., 1966; Hillcoat and Blakley, 1966;
Nixon and Blakley, 1968). Two enzymes have been shown 
to be present in the SF/A strain; a 'mutant'-type enzyme 
which is only just demonstrable in the parent, SF/O, 
strain, and a 'wild'-type enzyme which contributes nearly 
the total amount of the SF/O reductase. The resistance 
of the SF/A dihydrofolic reductase may be attributed to 
the production of a large amount of the 'mutant'-type 
enzyme. The 'wild'- type enzyme has a molecular weight 
of 28,000, while the 'mutant' enzyme's molecular weight 
is 20,000.
Hutchison and her colleagues have isolated 23 
spontaneous mutants of Diplococcus pneumoniae, all with 
varying degrees of MTX-resistance (Sirotnak et al., 1964b). 
The mutations occur at two distinct sites of the genome 
(Sirotnak et al., 1964). One mutation causes the 
production of an enzyme with a lowered affinity for MTX, 
and three related mutations cause the synthesis of elevated 
levels of the enzyme.
Phage infection of Escherichia coli cells produces 
elevated levels of dihydrofolic reductase, which differs 
from the parent enzyme, and appears to speed viral 
replication (Mathews 1966).
. ■  . •  • '  i
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(VII) Substrate specificity of dihydrofolic reductase 
In general dihydrofolic reductase has a broad
substrate specificity. The presence of the glutamic acid 
residue is important for the effectiveness of the substrate 
(Blakley and McDougall, 1961). The affinity of the 
substrate is decreased when this residue is replaced by 
various other amino acids (Plante et al., 1967), or when it 
is absent (Zakzewski, 1960b).
Such substances as dihydroiodofolate (Misra, D., - 
unpublished data; Friedkin et al., 1962), folyl diglutamate 
and its derivatives, 3',5'-chlorodihydrofolate, in some 
cases 10-methyldihydrofolate, and 7,8-dihydrohomofolate, 
which has an additional methylene group between the 
dihydropterin and the p-aminobenzoylglutamate of 
dihydrofolate, all appear to be as effective substrates as 
FH^ itself. Kaufman (1962) has even reported the reduction 
of biopterin by dihydrofolic reductase.
(VIII) Mechanism of the dihydrofolic reductase catalysed 
reaction___________________________________________
Baker and Ho (1964) postulated that a histidine at
the active site participates in the hydrogen transfer that
takes place during the reduction of F and FH^ by
dihydrofolic reductase. If the imidazole ring of the
histidine is placed in juxtaposition with the pyrazine ring
of F,' then one imidazole tautomer could readily transfer a 
proton to N(8) of the pteridine, while the other tautomer could
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transfer a proton to the N(5). NADPH is assumed to be 
positioned on the opposite side of the pteridine from the 
imidazole so that it could readily transfer a hydride ion 
to either the C(7) or the C(6)of the pteridine.
However, experiments involving tritium and deuterium
%
labelling have indicated that dihydrofolic reductase could 
catalyse the same transfer reaction twice to accomplish the 
two-step reduction of F to FH^ (Zakrzewski, 1966). During 
the reduction of F to 7,8 - FH^ a hydride ion is thought to 
be transferred from NADPH to the C(7) of F. Subsequently, 
intramolecular rearrangement of 7,8 - FH^ could take place, 
presumably to form 5,8 - FH^, and then the second hydride 
ion from NADPH would be transferred again to position C(7) 
of the pteridine to form FH^. The above hydrogen transfers 
are stereospecific (Mathews and Huennekens, 1960). Chicken 
liver reductase produces a single diastereoisomer with 
(oC)^  - 16.9° as compared with (c<)^  + 14.9° for the non- 
enzymically formed (-) L - FH^.
The equilibrium constant for the enzymic reduction 
of FH^ by NADPH is very large. Nixon and Blakley (1968) 
gave a value of 0.8 - 0.16 x 10”.
It was thought that a sequential reaction mechanism 
would be operational for the dihydrofolic reductase 
catalysed reaction, because where nicotinamide adenine
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dinucleotides are involved in oxido-reductions, the 
reaction usually takes this form. In this event, NADPH 
would bind to the enzyme first, followed by FH^, with 
the release of FH^ preceding the release of NADP.
However, calculations of dissociation constants for the 
various substrates, inhibitors and cofactors indicate 
both random and sequential mechanisms (Perkins and 
Bertino, 1966).
NADP, NADPH and FH^ can all protect the L1210 
lymphoma enzyme from inactivation by moderate heat and 
urea (Perkins and Bertino, 1966). This suggests a 
random reaction mechanism, as does the decreasing of the 
rate of the PCMB-stimulated enzyme reaction by NADPH and 
FH^ (Perkins and Bertino, 1966).
(IX) The binding of folate and dihydrofolate to dihydrofolate 
reductase_________________________________________________
It would appear that the substrates, folate and
dihydrofolate, of dihydrofolic reductase are mainly bound
to the enzyme by specific groups on the pteridine and
p-aminobenzoylglutamate moieties of these substrates.
Little is known about the binding of the pteridine
2
moiety to the enzyme, but as 2-deaminofolic acid and N ,
2
N -dimethyfolic acid are not substrates for dihydrofolic 
reductase it would appear as though the 2-amino group of
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the pteridine is essential for substrate properties 
(Bertino et al., 1965b). The binding of this group 
of the substrate to the enzyme is thought to be by 
hydrogen bonding (Johns et al.,•1964b).
The importance of the p-aminobenzoylglutamate 
moiety for substrate binding to the enzyme is shown 
by the 100,000 times weaker binding of 6-methylpterin 
than F to chicken liver reductase (Zakzewski, 1963).
It has been suggested that the p-aminobenzoylglutamate 
moiety is bound to the enzyme through the formation of 
a charge transfer complex between the benzene ring and 
an electron-rich area of the enzyme, where the p-carboxyl 
group would withdraw electrons from the benzene ring to 
make it a better electron acceptor (Baker and Jordan,
1965). The importance of the ^-carboxyl in the binding 
of the glutamate moiety to dihydrofolic reductase is 
demonstrated by the reduction in binding of both MTX 
(Baker, 1967a) and folic acid (Zakzewski, 1960b) when the 
glutamate part of the inhibitor and substrate respectively 
is replaced by aspartate.
Binding of the hydrogen on the of folic acid and
FH^ to the reductase could occur, but experiments with 
10-formyl folic acid did not show a decrease in binding, 
but a 16-fold enhancement. This is probably due to the
I
effect of the N-formyl group on the pyrimidal, CH^ - N - ,
3]
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moiety of folic acid, which is made planar by amide 
formation, and could result in a more favourable 
groundstate conformation for binding to the enzyme 
(Baker et al., 1966).
%
(X) Inhibitors of dihydrofolic reductase and their 
possible mode of binding to this enzymie_______
The development of antifolates as effective
chemotherapeutic agents has led to investigations on
the interaction of closely related substances of folic
acid with dihydrofolic reductase by varying the
substitutent groups of this compound.
The most effective analogues of the pyrimidine 
derivatives as inhibitors of dihydrofolic reductase are 
the 2 ,4-diajnino-pyrimidines having the general structure
N H 2
N R,
R.
where (CH^)^ and R^ = CH^ or n - (Baker
and Ho, 1965b); pyrimethamine, which has the structure :-
N H
Cl
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/
— 8and an apparent of 1.7 x 10 M for the enzyme from 
Ehrlich ascites cells (Bertino et al., 1965b), where
is the dissociation constant of the enzyme-inhibitor 
complex, and certain 4,6-diamino-l,2dihydro-S-triazines, 
where n = 3 , 4 or 5 , e.g. the substituted triazine given 
below :- ‘
(Baker and Ho, 1965a, 1966; Baker et al., 1967a).
MTX and aminopterin are the most tightly bound 
pteridine inhibitors. The replacement of the 4-hydroxy 
group of F by a 4-amino group, as in aminopterin, gives 
a tremendous enhancement in binding, about 3,000-fold.
N H R
CH^M '^CONHCHC o Oh
CH^CH^COOH
R=K; aminopterin 
CHg ; MTX
The exact nature of this binding is not known, but has 
been suggested by Baker (1959) to be due to the more 
basic nature of the 2,4-diamino compounds, which will more 
readily form a protonated species and complex with an 
anionic site on the enzyme. He has also implicated this 
acidic function of the enzyme in the rotation of various
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heterocyclic inhibitors , which would permit the 
orientation of their side chains to give maximum 
binding to the p-aminobenzoylglutamic binding site 
and the hydrophobic binding site described below 
(Baker and Shapiro, 1966).' Zakzewski (1963), however, 
infers that hydrogen bonds are important, as F would 
have to change to a less favourable tautomer to achieve 
the same binding as the 2,4-diamino derivative.
Studies with various pyrimidine-type inhibitors
having the general structure :-
OH
N
CH3
led to the discovery of an extremely strong hydrophobic 
binding region on the enzyme (Baker, 1967a). Replacement 
of the anilino nitrogen of the moiety, - (CH^)^
NH—<^ ^ , by a CH^ group to give -(CH^)^ — < ■\
produced a 27-fold increase in binding. A similar 
substitution for the folic acid analogue and the 2,4- 
diaminopyrimidine series gave a 4-fold and an 80-fold 
enhancement in binding respectively. This suggested that 
the replacement of the p-aminobenzoylglutamate moiety of 
aminopterin by a benzoyl group should give a better 
inhibitor than aminopterin, but on the contrary inhibition
    ■ _ ' ___ _ _ _• ____ _______________ . , . . i
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was less. This discrepancy was resolved by synthesising 
the 5 - n -butyl pyrimidine without the 5-substituent.
Because the n-butyl group can only complex to an enzyme , 
by a combination of hydrophobic and Van der Waals forces, 
this led to an extensive study of the hydrophobic bonding 
to dihydrofolic reductase.
Exploitation of the hydrophobic binding region of 
the enzyme has enabled compounds to be produced, which 
will specifically inhibit dihydrofolic reductases from 
different sources in an irreversible manner (Baker et al., 
1969). These compounds were synthesized on the assumption 
that the hydrophobic binding region is distinct from the 
active site (Baker, 1967a), and exhibits differences in 
amino acid composition depending on the source. This is 
plausible since the hydrophobic region is non-functional 
in respect to tie binding of F and FH^ as substrates (Baker 
et al., 1966). The irreversible inhibitors of dihydrofolic 
reductase bind specifically to the hydrophobic area of the 
enzyme, and have been designed to have side chains which 
carry functional groups capable of alkylating suitable 
groups on the enzyme surface. Such groups on dihydrofolic 
reductase could include those that are involved in the 
binding of the glutamate of FH^ to the enzyme, or the 
imidazole ring of the histidine, which is located at the
1
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active site and participates in the hydrogen transfer 
reaction (Baker and Ho, 1964).
(XI) Species differences in dihydrofolic reductase 
inhibition__________ '__________________________
The structure of the ^active site of dihydrofolic 
reductase from pigeon liver, E. coli, E. coli infected 
with phage. Walker 256 rat tumour and mouse lymphoma, 
L1210/FR8,are very similar (Baker and Ho, 1965c; Baker 
and Jordan, 1967; Baker, 1967b ; Baker and Lourens, 1967,
1968a ; b , and c ; Baker et al. , 1967b), but there are 
conformational differences in the hydrophobic region of 
the enzyme due to alterations in the primary sequence 
as evolutionary development is achieved. Very striking 
differences have been observed by Burchell and Hitchings 
(1965) in the binding of inhibitors to mammalian, protozoan 
and bacterial reductases. This provides an explanation for 
the chemotherapeutic effectiveness of such drugs as 
trimethoprim and pyrimethamine in the treatment of certain 
diseases (Hitchings, 1967 ; Ferone et al. , 1969).
Evidence suggests that human dihydrofolic reductases 
differ structurally from other mammalian enzymes, as antibody 
against dihydrofolic reductase from mouse L1210 R tumour 
cells only partially inactivates the enzyme isolated from 
human bone marrow, and does not inactivate the enzymes 
isolated from mouse or chicken liver (Perkins et al., 1969).
- 31 -
Jarabak and Bachur (1971) have obtained evidence that 
alterations in the glutamate moiety of MTX may not have 
identical effects on human and rodent enzymes.
/-
(XII) The 4-amino analogues of folic acid as inhibitors 
of dihydrofolic reductase_____________ ___________
The 4-amino analogues of F have been shown to be
potent inhibitors of dihydrofolic reductase in animal
tissues (Futterman and Silverman, 1957; Osborn et al.,
1958; Misra et al. , 1961; Bertino et al. , 1960 ; Nath and
Greenberg, 1962; Zarzewski, 1960a ; Werkheiser, 1961)and
in bacterial tissues (Blakley and McDougall, 1961). They
are, perhaps, the most tightly bound dissociable inhibitors
yet studied (Werkheiser, 1961).
The type of inhibition that they exert on this 
enzyme has been shown to be stoichiometric (Werkheiser,
1961 ; Bertino et al. , 1964). Inhibition of this nature 
has previously been described by Straus and Goldstein 
(1943), Ackerman and Potter (1949), Lowry et al. (1949),
Reiner (1959) and Webb (1963). Stoichometric inhibition 
is characterised by the apparent small dissociation of the 
enzyme-inhibitor complex as compared to the enzyme 
concentration. Thus, at concentrations of inhibitor 
inadequate to cause inhibition of the enzyme practically 
all the inhibitor is enzyme-bound. As the Lineweaver-Burk 
treatment of enzyme inhibition assumes that the inhibitor
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is freely dissociable, the classical equations are not 
applicable. However, the following equation may be used 
for all types of stoichiometric inhibition (Goldstein, 
1944).
where E is the concentration of the inhibitor-binding 
sites on the enzyme, I the total concentration of the 
inhibitor, S the concentration of the substrate, the 
dissociation constant for the enzyme-substrate complex,
V the velocity of appearance of product or disappearance 
of substrate and the velocity when the enzyme is
saturated with substrate. Like the conventional equation 
describing non-competitive inhibition this equation 
increases both the slope and the intercept of the plot 
of 1/v versus 1/S by the same factor. Thus, many workers 
concluded wrongly that dihydrofolic reductase was inhibited 
noncompetitively (Osborn et al., 1958; Blakley and McDougall, 
1961; Nath and Greenberg, 1962). However, stoichiometric 
inhibition can clearly be dist^inguished from non-competitive 
inhibition from a study of the effect of enzyme concentration 
on the activity at a constant drug concentration as 
recommended by Ackerman and Potter (1949). The latter type
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of inhibition will result in a rectilinear plot of 
activity against enzyme concentration of lesser slope 
than the control, which passes through the origin, while 
stoichiometric inhibition gives a line, which is parallel 
to the control, and does not pass through the origin.
Goldstein (1944) also showed that stoichiometric inhibition 
is characterised by a lack of effect of dilution of the 
enzyme-inhibitor mixture upon the concentration of the free 
inhibitor.
Bertino et al., (1964) were able to show at pH 7.5,
where there is some degree of reversibility, that a competitive 
relationship does exist, i.e. that the inhibitor does react 
with the active centre of the enzyme. A of 6.7 x 10’'^^M 
was obtained under these conditions.
The enzyme-inhibitor complex is dissociated by 
chromatography on hydroxylapatite aind DEAE-cellulose (Mathews 
and Huennekens, 1963), and for some enzymes by strong 
ammonium sulphate solutions (Silber et al., 1963).
Werkheiser (1961) showed that tritiated aminopterin 
and MTX were tightly bound to the soluble fraction of rat 
liver homogenate. Dialysis against 1,000 volumes of 0.25 M 
sucrose at 4°C for three periods of 24 hours gave an 
extremely small loss of inhibitor from this soluble fraction.
At most 15% of the drug was lost.
.-  3 4  -
2. THE FOLIC ACID ANTAGONISTS
(I) Discovery of the folic acid antagonists
The first folic acid antagonists to be used as 
chemotherapeutic agents were the sulphonamides, which 
were known to have antibacterial properties. Their 
inhibitory effects could be overcome by the administration 
of p-aminobenzoate (Woods, 1940). It was only later 
suggested that this substrate functioned in some way in 
the biosynthesis of folic acid, various nucleic and amino 
acids (Shive and Roberts, 1946); its importance was first 
realised when it was shown that the molecule of 
pteroylglutamic acid contained one p-aminobenzoic acid 
residue (Angier et al., 1946). The role of sulphonamides 
as competitors of p-aminobenzoate has since been clarified 
by investigations of the biosynthesis of folate at the 
molecular level (Brown, 1962 ; Hitchings and Burchell, 1965; 
Woods, 1962).
Since the discovery in 1940 by Woods that substitution 
of a functional group on a metabolite could result in a 
compound that would act in a competitive manner in vivo, 
there has been a widespread search for chemotherapeutic agents 
among structurally related compounds. In 1948, Farber et al. 
showed that aminopterin produced remissions in children with 
acute leukaemia, which stimulated great efforts in 
antimetabolite therapy in cancers. A series of analogues
~LJ
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of aminopterin, as well as MTX were synthesised and 
tested for their ability to produce regressions in a 
number of transplantable mouse tumours (Sugiura et al.,
1949; Stock et al., 1950). It appears as though the
4-amino group in this series of antimetabolites is
%
necessary for significant anti-tumour activity (Goldin 
et al., 1957).
(II) The site of action of the 4-amino analogues of 
folic acid______________________________________
Direct evidence of inhibition of F reduction to
FH^ by the folic acid antagonists was obtained by Nichol
and Welch (1950) through estimating microbiologically
the formation of the FH.-derivatives in rat liver slices4
upon the addition of F in the presence or absence of 
aminopterin. Similar observations were made by Condit 
and Mead (1963) and Condit (1961) who found that 
subcutaneously injected MTX inhibited the rise in level 
of mouse liver FH^-derivatives. Interference with the 
coenzymic activities of F by MTX was first implied when
5-amino -4-imidazole - carboxamide ribotide was found to 
be accumulated intracellularly upon exposure to the drug 
(Tomisek et al., 1958). This accumulation was the result
of inhibition of the formylation of this compound, a reaction 
which is normally mediated by FH^-derivatives, the carriers 
of 1- carbon units in the cells.
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The in vivo studies of Werkheiser (1962) showed 
that 24 hours after aminopterin administration the 
molar concentration of aminopterin in the liver and 
intestinal mucosa is equal to that of the inhibited 
enzyme. Twenty four hours after the last of 4 daily 
injections of MTX, the hepatic dihydrofolic reductase 
in mice was inhibited 80 to 94% compared to the controls, 
i.e. enzyme extracted from animals receiving no MTX 
treatment. Concomitantly administered F, FH^ or 5-formyl- 
FH^ had no effect on the dihydrofolic reductase inhibition 
even though FH^ and 5-formyl-FH^ significantly reduced the 
toxicity of the antifolate (Mead et al., 1963).
It has been considered that MTX may be reduced to 
its FH^ -derivative in vivo, and may exert its action at 
sites other than dihydrofolic reductase. However, MTX 
persists in the mouse liver for more than 3 weeks after 
administration in an identical form to that given, as 
indicated by chromatographic experiments (Fountain et al., 
1953). The tetrahydro-derivatives of the folic acid 
analogues have been investigated as potential anti-cancer 
drugs (Mead et al., 1961a, b), but were shown to be 10 
times more toxic than the unreduced forms, and their 
growth inhibitory properties could easily be reversed in 
the bacteria, Streptococcus faecalis and Pseudomonas 
cerevisae, by 5-formyl-FH^, suggesting that the enzyme
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sites involved did not bind the reduced analogues tightly 
(Kisliuck, 1960).
Additional evidence for dihydrofolic reductase as 
the target site in the cell for folic acid antagonists 
comes from the work of Slavi^kova and Slavik (1961), who 
studied the inhibitory effect of the 4-amino analogues of 
co-enzymically active folic acid derivatives on enzyme 
systems which convert F to its co-enzymically active 1-C 
carriers and on serine aldolase and hydroxymethyl-FH^ 
dehydrogenase; aerobic formylases of F and FH^ were not 
inhibited. The enzyme system most strongly inhibited by 
aminopterin and by MTX was dihydrofolic reductase.
(Ill) Physiological distribution of MIX
Studies with rats (Henderson et al., 1965a), mice 
(Henderson et al., 1965a) and man (Henderson et al.,
1965a, b ; Johns et al., 1964a) have shown that MTX is 
incompletely absorbed from the intestinal tract. As much 
as 67 - 100% of the total dose of MTX ranging from 0.5 to 
25 mg/kg, is excreted in the faeces and urine in mice 24 
hours after administration. Similar figures have been 
obtained for man, where 37% to 88% of a small dose of MTX 
is excreted in the urine.
Although absorption from the intestine is apparently 
incomplete, it would appear that MTX is rapidly taken up by
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the tissues, since soon after administration of the 
antifolate the tissue: plasma ratios seen in mice are 
for liver 10:1, kidney 3:1 and muscle 0.1:1 (Zaharko 
et al., 1971). Fountain et al., (1953) also clearly
demonstrated-that MTX persists in certain mouse tissues 
such as liver and kidney for periods up to 8 months.
It is thought that even though the bone marrow and 
tumour tissues bind MTX and are affected by it, they do 
not play a significant role in determining the plasma 
concentration of the drug as are the liver, kidney, 
gastro-intestinal tract and muscle. Hence, the concentration 
of MTX in the former two tissues is probably in some way 
associated with the plasma level, and results from the 
combined action of such tissues as the liver and kidney 
(Zaharko et al., 1971).
As much as 50% of the total amount of MTX in the 
plasma has been reported to be bound to protein (Henderson
et al., 1965a), but this value has been obtained from
ultrafiltration experiments using the centrifugation method, 
and was suggested by Blakley (1969) to be too high as 
folates pass through semi-permeable membranes much more 
slowly than does water. MTX clearance from the plasma is 
not so rapid as F (Johns et al., 1964a; Henderson et al.,
1956b), and has a half-life of 134 minutes for doses in the
range of 0.1 mg/kg to 10 mg/kg.
. , ' ■    :__ ——— _J_____ IB
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Plasma levels following intravenous or oral
administration of MTX are proportional to the dose level
in man (Henderson et al., 1965b) and for various animal
species (Zaharko et al., 1971). Higher levels of MTX
persist in the plasma in man than in mice as 0.1 ug MTX
per ml plasma is maintained for approximately 24 hours in
man, whereas after 3 hours the plasma level rapidly decreases
to below that value in the mouse after administration of
2equivalent doses of 10 mg MTX/m (Zaharko, 1971). This 
dosage is often used to equate species toxicities with many 
chemotherapeutic agents (Freireich et al., 1966), and 
apparently works with MTX in mouse and man.
With constant infusion of MTX there is a rapid rise in 
level of MIX in all tissues, and a gut concentration 16 times 
that of the plasma concentration is often achieved (Zaharko, 
1971). Werkheiser (1962) found in the soluble fraction of 
mouse liver homogenate 24 hours after the administration of 
the analogue 10 mu mol aminopterin per g of soluble protein. 
Henderson et al., (1965a) expressing their results differently,
but probably in keeping with those of Werkheiser (1962), 
obtained values of 0.1 to 0.49 m(x mol of MTX per g of mouse 
liver 24 hours after the MIX dose was given. Analysis 
of the mouse liver homogenates indicates that 80 - 90% of the 
MIX is present in the supernatant fraction of the homogenate 
and is, therefore, presumably in the cytoplasm of the cell 
(Henderson et al., 1965a).
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MTX excreted in the urine of man is almost entirely 
in the form of unchanged MTX (Johns et al., 1964a;
Henderson et al., 1965b), but significant metabolism of
9
MTX by intestinal bacteria occurs in mice after 3 hours 
and rats after 6 hours (Zaharko et al. , 1969 ; Zaharko and 
Oliverio, 1970). There is some evidence that the bacterial 
metabolite in mice is also a dihydrofolic reductase inhibitor 
(Zaharko et al., 1971). In the guinea pig and rabbit an 
hepatic aldehyde oxidase catalyses the metabolism of MTX to 
its 7-hydroxy derivative at a significant rate (Johns et al., 
1966 ; Redetzki et al. , 1966).
(IV) Influx and Efflux of MTX in cells and tissues
MTX is poorly soluble in lipid and has a net negative 
charge, so it would be expected to have a slow influx rate 
into cells if its uptake relied on passive diffusion alone. 
However, evidence suggests that MTX uptake into cells is 
energy-dependent in several bacterial species, e.g. 
Streptococcus faecalis (Wood and Hitchings, 1959),
Lactobacillus plantarum (Wood et al. , 1961) , Bacillus subtilis 
(Pine, 1960a, b), Diplococcus pneumoniae (Johns and Loo, 1967) 
and in the following cell lines, Ehrlich ascites cell carcinoma 
(Kessel and Hall, 1967), the murine leukaemia cell line,
L5178Y, (Fischer, 1962), the L1210 mouse leukaemia cells 
(Sirotnak et al., 1968), the Yoshida sarcoma cells (Divekar 
et al., 1967), and in granulocytes from normal patients
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(Kessel et al. , 1968), while it would appear that the 
influx of MTX into small lymphocytes (Kessel et al.,
1968) and into the Sarcoma 180 cells (Hakala, 1965 a,b) ' 
is both slow and passive.
MTX can be accumulated in some cells so that the 
intracellular concentration is several times that of the 
external environment (Fischer, 1962; Divekar et al., 1967), 
and concentrations of tritiated MTX 12 times that of the 
extracellular fluid have been demonstrated for the rabbit 
kidney cortex (Loo and Adamson, 1962). Conflicting evidence 
is, however, presented by Hakala (1965 a,b) who showed that 
the intracellular concentration of MIX for Sarcoma 180 cells 
is low, and postulated an active efflux of the antifolate 
from the cells, while uptake is by passive diffusion. MTX 
is not always rapidly lost because such cells as those of 
the murine L5178Y leukaemia, when placed in a medium free 
of the antifolate, still retain much of their intracellular 
MTX after long periods of time (Fischer, 1962).
That passive diffusion into cells could be a possible 
mechanism of uptake of the drug was suggested because net 
influx could be increased by lowering the pH and raising the 
Ca^^ concentration of the medium. This was interpreted as 
operating through a decreased net charge in the MTX molecule 
(Hakala, 1965 a ,b ). Since ouabain is inhibitory for the 
uptake of MTX by the Yoshida sarcoma cells, it was postulated.
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in contrast to the above mechanism suggested for MTX 
uptake, that a Na"^, K^-activated ATPase of the plasma 
membrane was involved in the transport mechanism '
(Divekar et al., 1967).
Kessel and Hall (1967) postulated that the same 
active transport mechanism is operational for the uptake 
into the L1210 mouse leukaemia cells of MTX, aminopterin 
and closely related analogues, 5-formyl-FH^, and possibly 
F and its related compounds.
The loss of MTX from the liver and intestinal mucosa 
in mice is exponential (Werkheiser, 1962), with a half­
loss in 56 hours from the mucosa. MTX is removed from the 
liver in 2 phases; an initial rapid loss with a half-time 
of 64 hours, and a slower loss of the residual analogue 
which has a half-life of 92 days.
(V) The use of the 4-amino analogues of folic acid as 
chemotherapeutic agents___________________________
MTX, its dichloro derivative and other halogenated 
derivatives have been shown to be the most effective 
chemotherapeutic agents against the L1210 murine leukaemia 
(Goldin et al. , 1955a ; Venditti et al. , 1960; Goldin et al. ,
1959).
An increased therapeutic response as compared to
.Lj
- 43 -
administration of the analogue alone has been obtained 
in experimental animals when 5-formyl-FH^ is given 12 
to 24 hours after the antifolate (Goldin et al., 1953a;
Chubb and Laursen, 1954; Burchenal et al., 1950). This 
has been substantiated in adult patients with acute 
leukaemia, where large dose .intermittent infusion of MTX 
followed by administration of 5-formyl-FH^ has produced 
promising results (Hyrniuk et al., 1967). The increased 
therapeutic response would appear to be due to the action 
of the analogue on the leukaemic cells, while some protec­
tion is given by 5-formyl-FH^ to the host tissues (Goldin 
et al., 1954). The protection afforded by delayed 5-formyl- 
FH^ administration also permits higher doses of the folate 
analogue to be used with a further therapeutic advantage 
(Goldin et al. , 1955b ; Goldin et al. , 1966). However, when 
tumour-bearing animals are given 5-formyl-FH^ before or 
simultaneously with the folate analogue there is some 
protection against the toxic effects, but the anti-tumour 
activity is reversed (Burchenal, 1950; Goldin et al. , 1953a ; 
Chubb and Laursen, 1954).
Some relatively successful results have been reported 
for the use of folate analogues in the treatment of patients 
with Burkitt’s lymphoma (Bertino and Johns, 1967; Burkitt 
et al., 1965) where 10 - 20% of the patients showed no 
recurrence of the disease after 6 years, and in the treatment 
of choriocarcinoma (Ross et al., 1965), where an overall cure
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rate of 74% was obtained by the use of MTX and 
actinomycin D in sequence.
Long-term remissions have been produced by therapy
with antifolates in patients with acute leukaemia
(Burchenal, 1965), during which it was shown that
%
dihydrofolic reductase activity and thymidylate synthesis 
from tritiated deoxyuridine in peripheral blast cells were 
inhibited.
The use of combinations of drugs in cyclic therapy 
is under investigation for chemotherapy of acute lymphoid 
leukaemia in children (Bertino et al., 1967; Freireich e^ 
al. , 1965 ; Frei, 1965, Hananian et al. , 1965 ; Brubaker ejt 
al. , 1963), and of adult acute, myelogenous leukaemia 
(Thompson et al., 1965).
Most solid tumours are naturally resistant to 
therapy with the folic acid antagonists, but MTX therapy 
has produced some beneficial results in the treatment of 
squamous cell carcinoma of the neck, head and lung 
(Sullivan et al. , 1959 ; Heilman et al. , 1964 ; Huseby and 
Downing, 1962, Papac et al. , 1962 ; Ross and Selav/ry, 1965, 
1966 ; Condit et al. , 1964), and in cancer of the breast 
(Vogler et al. , 1965 ; Greenspan, 1964), and with oral 
administration of the drug for patients with various 
sarcomas (Wiltshaw, 1967).
J J
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Folate antagonists have been used for therapy in 
non-neoplastic diseases, such as psoriasis (Rees and 
Bennett, 1959; Van Scott et al., 1964), and in the 
suppression of the immune response (Santos, 1967;
Berenbaum, 1963). Malaria and toxoplasmosis are treated 
with the 2,4-diaminopyrimidines (Hitchings, 1960).
It is hoped that a more selective action of these 
drugs against neoplastic cells will be obtained by 
exploiting those qualities which single out the neoplastic 
cells from the normal cells of the body (Hakala, 1969).
For example, leukaemic cells have a diameter of 9\i (Sirotnak 
et al., 1968) while other mammalian cells have a diameter of 
approximately 20jr, and correct use of this difference in 
size with regard to increased drug uptake as the ratio of the 
surface area to the volume becomes larger, might well contribute 
to success in the chemotherapy of leukaemias (Hakala, 1969).
One must also consider the importance of the generation time 
of the target cells, especially when DNA synthesis is the 
immediate object of inhibition, as shown by Lichter et al.
(1964) who found that MTX at a concentration of lO'^M was 
required to kill KB cells in one hour, and at a concentration 
of 2 X  10 '^ M to kill them in 3 days, while 5 to 8 x 10 MTX 
was usually needed to kill them in 6 to 7 days.
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(VI) Toxic effects of folate analogues in experimental 
animals and man___________________________________
The toxic effects of MTX and aminopterin are similar 
in experimental animals and man (Burchenal et al., 1951; 
Schoenbach et al., 1952; Trier, 1961). Significant weight 
loss can be detected 24 hours after drug administration in 
rats, dogs and mice, and later effects are manifested as 
anorexia, diarrhoea, progressive depression and terminal 
collapse and coma (Philips et al., 1950).
Inhibition of mitosis of crypt cells is detectable 
within 3 hours of aminopterin administration (Zamcheck,
1960). Multiple haemophagic and morphological ulcerations 
are produced in the lower gastrointestinal tract.
Maturation of erythrocytes in the bone marrow is 
affected, resulting in increased production of megaloblasts 
(Philips et al., 1950). Some expulsion of nuclear fragments 
from immature erythrocytes also occurs. Myelopoiesis is also 
affected; hypersegmentation of polymorphonuclear neutrophils 
gives rise to giant metamyelocytes.
Folate analogues are more toxic to experimental 
animals when given in repeated doses, such that the median 
lethal dose (LD^^) of MTX for rats is 14.7 mg/kg body weight 
for a single dose, but is 6.0 mg/kg body weight when 
administered over a period of 5 days, a single injection
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being given daily (Philips et al., 1950). Animals
receiving a fatal dose survive for at least 48 hours and
die usually after 3 to 5 days (Philips et al., 1950).
Rats are more sensitive to folate analogues than mice, male
and female rats being equally sensitive (Ferguson et al.,
%
1950) .
(VII) Reversal of toxic effects of folate analogues in 
experimental animals and man______________ .______
FH^ is more effective than F in counteracting the
toxicity of MTX (Condit and Mead, 1963). FH^ can cause
significant displacement of labelled MTX from tissues, in
contrast to the small displacement observed with F (Johns
et al., 1964a). FH^ is reduced several hundred times more
rapidly than F by dihydrofolic reductase at neutral pH, so
that significant amounts of FH^ from FH^ could be produced
from any residual enzyme activity remaining after MTX
inhibition (Condit and Mead, 1963). This could account for
the reversal by FH^ of the toxic effects of MTX, while
5-formyl-FH^, which also reduces the toxicity of the folate
analogues, 5-methyl-FH^ and FH^ cause only a small
displacement of labelled MTX from tissues of dog (Bertino,
1963) and man (Johns et al., 1964a). It is most likely that
FH^ and its derivatives reverse the toxicity of the folic
acid antagonists by by-passing the block at dihydrofolic
reductase (Werkheiser, 1963; Charache et al., 1960).
-  4 8  -  •
Goldin and his co-workers (1952, 1953a) showed that
5-formyl-FH^ will protect mice against the toxic 
effects of aminopterin much more effectively than F, 
so that the LD-^ for aminopterin is proportional to the 
amount of 5-formyl-FH^ administered.
(VIII) The effect of folate analogues on tissue culture cells
Jacobson (1954 a,b) has shown that MTX and aminopterin 
arrest the division of embryonic chick fibroblasts and 
osteoblasts. Within 15 minutes of adding 1 mM to 0.1 mM 
aminopterin to the culture medium, dividing cells are 
arrested at metaphase. These metaphase chromosomes form a 
tight cluster.
The inhibition of growth by MTX of S-180 cells 
(Hakala, 1957; Hakala and Taylor, 1959; Hakala et al.,
1961), Hela cells (Hakala and Taylor, 1959; Loh, 1960;
De Mars and Hooper, 1960; Rueckert and Mueller, 1960) and 
the J-111 cells (Hakala and Taylor, 1959) derived from a 
human monocytic leukaemia can be reversed by the addition 
of glycine, thymidine and either adenine, hypoxanthine or 
the corresponding nucleosides of these purines to the growth 
medium. In the absence of a purine, MTX causes S-180 cells 
to disintegrate even when thymidine and glycine are present 
(Hakala, 1957; Hakala and Taylor, 1959; Hakala et al., 1961).
L
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Hela cells exhibit a thymine deficiency similar to 
that produced by 5-fluoro-2*-deoxyuridine (FUdR) when 
grown in the presence of purine, glycine and MTX. Cell 
division and DNA synthesis decrease while RNA and protein 
synthesis continue to take place (De Mars and Hooper,
1960; Rueckert and Mueller, 1960). The ratio of RNA and 
protein to DNA was greater in folate analogue-inhibited than 
in untreated cells (Loh, 1960; Rueckert and Mueller, 1960), 
which suggests that the blocking of thymidylate synthesis is 
the most far-reaching effect of MTX.
Mouse leukaemic cells grown in the presence of 
2 X 10 M MTX for one week are still able to cause clinical 
manifestations of the disease when transferred back into 
mice (Kieler and Kieler, 1954).
(IX) The effect of folate analogues on bacteria, yeasts 
and invertebrate animals____________________________
Streptococcus faecalis and Lactobacillus casei have 
a nutritional requirement for F or its derivatives, and are 
more sensitive to inhibition by MTX than Pediococcus 
cerevisiae (formerly Leuconostoe citrovorum), which requires 
a supply of 5-formyl-FH^ or other FH^-derivatives for growth 
(Kisliuk, 1960; Zakrzewski et al., 1962; Kisliuk and Levine,
1964).
The 2,4-diaminopyrimidines and closely related folate 
analogues are effective growth inhibitors of protozoan_______
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parasites, such as Plasmodia (Hitchings, 1960, 1962;
Falco et al. , 1951 ; Russel and Hitchings, 1951), Toxoplasma, 
Eimeria and Tetrahymena pyriformis (Dewey and Kidder, ’1953 ; 
Kidder, 1954). These drugs have been extensively used in 
the treatment of malaria. Trimethoprim has chemotherapeutic 
uses, as it preferentially inhibits the dihydrofolic 
reductase of bacteria (Hitchings et al. , 1952 ; Burchenal 
and Hitchings, 1964).
The larvae of Drosophila melanogaster are retarded in 
development and have an increased mortality rate when grown 
in the presence of antifolates, such as MTX, aminopterin and 
pyrimethamine (Goldsmith et al. , 1950 ; Schultz et al. , 1955). 
Feeding of aminopterin to the housefly. Musea domestica, 
prevents ovarian development and causes sterility in females 
but not in males (Mitlin et al., 1957).
(X) Other effects of folate analogues in experimental animals
Nelson et al., (1952, 1955, 1956) have shown that
foetal death occurs in rats when crude *X^-methylfolic acid 
is administered during the 7th to 9th day of pregnancy, and 
differentiation and organogenesis is affected when administration 
of the drug takes place during a 48.hour period between the 7th 
and 15th day of pregnancy.
Aminopterin inhibits the oestrogen-elicited growth of 
the oviduct of stilboestrol-treated chickens (Hertz, 1948 ;
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Hertz and Tullner, 1950). It also inhibits the growth 
of the female genital tract of oestradiol-treated, 
ovarisectomised rats (Hertz and Tullner, 1950), and the  ^
growth of the oviduct in frogs (Goldsmith et al., 1948, 
1950b).
Intraperitoneal injections of MTX decrease wound 
healing in rats (Calnan and Davis, 1965).
(XI) Resistance to Folate analogues
Leukaemic cells initially sensitive to the action 
of folate analogues develop resistance to these drugs 
(Law, 1956). This ^acquired* resistance is stable and 
heritable in the mouse L1210 MTX-resistant leukaemia (Law 
and Boyle, 1950; Law, 1951) and in the Ehrlich ascites 
MTX-resistant carcinoma (Misra et al. , 1961). In some 
cell lines made resistant to the action of MTX, the 
resistance appears to be correlated with the loss of a 
subtelocentric marker-chromosome present in the parent 
strain (Schrecker et al., 1963; Biedler et al., 1963). 
However, Law (1956, 1958) has observed an unstable MTX- 
resistant plasma cell neoplasm, the resistance of which 
was reversed on removal of the drug. ^Acquired * resistance 
possibly takes place by the inhibitor selecting those cells 
which naturally have a resistance to the drug. Mutants 
arising independently of the drug may also be selected in
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a similar manner (Emmelot, 1965).
Decreased uptake of folate antagonists as a 
mechanism of resistance to these drugs has been '
reported for the bacteria, Bacillus subtilis (Pine,
1960a) and Diplococcus pneumoniae (Sirotnak et al.,
1967); in the murine L5178Y leukaemic cells (Fischer,
1961) and for the transplantable L1210 leukaemia 
resistant to MTX (Sirotnak et al., 1968). MTX-sensitive 
leukaemias generally have a greater capacity for MTX 
uptake than the corresponding MTX-resistant leukaemia 
(Kessel et al., 1968). A ’natural* as opposed to 
’acquired’ resistance to MTX of neoplastic cells has been 
associated with a diminished transport of the drug into 
the cell, as those resistant mouse leukaemias, which have 
an impaired uptake of the drug, have not been obtained by 
repeated passage through hosts receiving the folate 
analogue (Kessel et al., 1965).
Certain MTX-resistant neoplasms are very sensitive 
to folate deficiency in the host, while the MTX-sensitive 
neoplasms are little affected under similar conditions 
(Rosen and Nichol, 1962 ; Potter and Briggs, 1962 ; Rosen 
et al., 1964). This could be explained along the lines 
of decreased MTX-uptake with increasing resistance, if MTX 
and folate transport in these cells are by one and the
X]
- 53 -
same mechanism. However, it has often been observed 
that children undergoing folate analogue-therapy during 
the terminal stages of acute leukaemia show severe signs» 
of folate deficiency in their normal tissues, while the 
leukaemic cells would appear to have a greater affinity 
for F or folinic acid and to be utilising the last traces 
of the vitamin (Jacobson, 1961 a,b). Alternatively the 
leukaemic cells could synthesise F and then folinic acid 
from precursors, a quality not shared with normal cells. 
Jacobson (1965) suggests that the reduction of F could 
occur via a pathway that is not blocked by folate 
antagonists and requires xanthine oxidase, an enzyme 
which under certain conditions could transfer hydrogen 
to F or FH^ (Jacobson and Good, 1952).
Elevated levels of dihydrofolic reductase with 
increasing MTX-resistance have been observed in the 
bacterium, Diplococcus pneumoniae (Sirotnak et al., 1964b), 
in the mammalian Sarcoma 180 cells (Hakala, 1957; Hakala 
and Taylor, 1959) and in the Ehrlich ascites carcinoma 
cells (Ryan et al., 1965). Those antifolate-resistant 
neoplasms selected by repeated passage through hosts 
receiving a large dose of the analogue, generally show raised 
levels of this enzyme (Misra et al. , 1961 ; Friedkin et al. , 
1962a ; Roberts et al. , 1965). Similarly leukaemic patients 
treated with folic acid antagonists exhibit elevated levels
^ ' ' ' : :  ^  ^ IE
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of dihydrofolic reductase in their leukaemic cells, and 
also in their normal leukocytes and erythrocytes.
However, these levels can be shown to be present even 
before a MTX-resistance appears (Bertino et al., 1962,
1963a, 1965a). Blakley (1969) has suggested that elevated 
levels of the enzyme appear 'in the immature cells in 
response to the formation of the enzyme-inhibitor complex 
between dihydrofolic reductase and the antifolate. This 
complex is believed to be resistant to the reactions that 
normally degrade the enzyme as the cells mature. In vitro 
studies on lymphoblast-like cells give support to the 
above suggestions (Hillcoat et al., 1967).
Of interest, is the suggestion by Misra et al.,
(1961) that the increased levels of dihydrofolic reductase 
in leukaemic cells could be exploited chemotherapeutically 
by designing folate analogues that are inactive in the 
oxidised form, but in vivo would be reduced rapidly by the 
high levels of the enzyme. Homofolate is such an analogue 
and requires for its activation reduction by dihydrofolic 
reductase, but was found to be only slightly more active 
against MTX-resistant sublines of S-180 cells than the 
parent strain (Nichol and Hakala, 1966).
Okada et al. (1960) have obtained an MTX-resistant
mutant of E. coli with an impaired thymidylate synthetase 
activity (Wilson et al., 1966; Bertino and Stacey, 1966).
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The inhibition of dihydrofolic reductase activity by 
MTX will not have much effect; the intracellular pool 
of methylene-FH^ will not be depleted, since these cells ^ 
now rely on an external source of thymine for growth.
Jacobson (1954c) and Jacobson and Cathie (1960), however, 
subjected chick osteoblasts to successive MTX treatments 
and showed that these cells were as sensitive to each 
application of the inhibitor, concluding that chick 
osteoblasts were unable to adjust to an alternative pathway 
independent of dihydrofolic reductase activity.
Mouse liver, cells from an acute lymphoblastic mouse 
leukaemia, normal human red blood cells and the bone marrow 
from children with acute leukaemia, converted aminopterin 
to an inactive form in vitro (Jacobson, 1954c), while normal 
mouse bone marrow, normal mouse lymphoblasts and lymphocytes 
and mature human lymphocytes were unable to do so. The 
inactivation of MTX is thought to take place by a ring 
closure of the terminal glutamate (Jacobson and Cathie, 1960), 
and may be a mechanism by which MTX-resistance occurs.
MTX-resistance in organisms has also been associated 
with the production of altered forms of dihydrofolic 
reductase in mutants of Diplococcus pneumoniae (Sirotnak 
et al., 1964b) and formation of a large amount of the ’mutant’- 
type enzyme in the SF/A strain of S. faecalis (Albrecht et al., 
1966 ; Hillcoat and Blakley, 1966 ; Nixon and Blakley, 1968).
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Mell et al. (1968) have shown that two dihydrofolic
reductase enzymes from a chicken liver extract show 
small differences in their sensitivity to MTX.
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3. PURPOSE OF INVESTIGATION
Resistance to anticancer drugs could be the result 
of changes occurring in the tumour, and/or a physiological 
adaptation of the host to reduce the effective concentration 
of the agent. Reizenstein (1961) has suggested that these 
phenomena should be treated separately. From a systemmatic 
study of a number of animal species, Zaharko et al. (1971)
noted that the liver and kidney are the main organs 
determining the level of MTX in the plasma, which, in turn, 
influences the amount of the antifolate reaching such tissues 
as the bone marrow and tumour, if present. Because of these 
reasons it was thought desirable to study the effect of MTX 
administration on the rat liver in non-tumour-bearing animals
The mechanism by which the folic acid antagonists 
exert their cytostatic activity is generally accepted to be 
a result of their ability to inhibit powerfully dihydrofolic 
reductase, a key enzyme in DNA synthesis. In consequence, 
any changes of the host tissue or tumour arising from 
continued antifolate therapy would be expected to result 
in variation of the activity and recovery from inhibition of 
this enzyme in vivo, and these variations could be used as 
markers in preliminary experiments for changes occurring in 
rat liver after treatment with MTX. Similar uses of 
dihydrofolic reductase as a chemotherapeutic index in the 
antifolate therapy of certain leukaemias have already been
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reported (Humphreys et al., 1962).
Investigations into the biochemical mechanisms of 
observed changes in dihydrofolic reductase activity in » 
the rat liver were.subsequently undertaken.
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B. MATERIALS AND METHODS
1. CHEMICALS
MTX was kindly donated by Lederle laboratories. 
Radioactive MTX (3’5 ’ , specific activity 6.8 Ci/mM)
was obtained from the Radiochemical Centre, Amershan. 
Solutions of MTX for in vitro experiments and for 
injection with tritiated MTX were made by the drop-wise 
addition of NaOH, and subsequently adjusted to pH 7.4 
with 0.1 N HCl. A solution of the sodium intraparenteral 
form in distilled water was used for all other animal 
injections.
NADPH and MTT, (3-(4,5-dimethyl thiazolyl-2-)-2,5- 
diphenyl tétrazolium bromide) were purchased from Sigma; 
ribonuclease, ^-globulin, ovalbumin and bovine serum 
albumin from Koch-Light. Sephadex G-lOO was obtained from 
Pharmacia and folic acid from BDH. Fresh solutions of FH^ 
were prepared immediately before use by the reduction of F 
to the dihydro form with sodium dithionite (Mathews, 1962a).
2. PURIFICATION OF DIHYDROFOLIC REDUCTASE
(I) Partial purification
5 g of liver was usually homogenised in 10 ml 0.1 M 
Tris-HCl pH 7.4 using a Potter-Elvehjem homogeniser with a 
teflon pestle. The homogenate was centrifuged at 100,000 g 
for 1 hour in an MSE 25 centrifuge, and the enzyme prepared
X-  6 0  -
from the supernatant fraction of the homogenate according 
to the method of Stanley et al. (1969) by precipitation
between 40 and 90% saturation with solid ammonium sulphate. 
The enzyme was dissolved in 2 ml 0.1 M Tris-HCl pH 7.4 and 
dialysed overnight against 0.01 M Tris-HCl pH 7.4. After 
dialysis the solution was centrifuged at 100,000 g for 20 
minutes, and the precipitated protein discarded. All 
manipulations were carried out in the cold.
The procedure was scaled up, so that enzyme was 
extracted from as much as 20 g of liver, if after ammonium 
sulphate fractionation the enzyme preparation was to be 
further purified by Sephadex G-lOO chromatography.
(II) Preparation of highly purified enzyme extracts
A jacketed glass column (1.7 x 153 cm) cooled to 12°C 
with running water was packed with Sephadex G-lOO, which 
had previously been allowed to swell in water for at least 
48 hours. The column was equilibrated with Tris-HCl buffer 
pH 7.4 (0.05 M containing 0.1 M KCl), which was also used as 
the eluting medium. Chromatography was carried out at the 
above temperature on 10 ml partially purified dihydrofolic 
reductase extract containing approximately 200 mg protein.
2.0 ml fractions were collected at a flow rate of 0.43 ml/min 
Enzyme preparations of higher purity were obtained by pooling 
separately the active fractions from each enzyme peak, 
reducing their volume by lyophilisation and recycling them
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on the Sephadex G-100 column.
Table 1 summarises the overall purification of
r
dihydrofolic reductase, and represents the procedure 
carried out on enzyme extracted from animals, which had 
received no injections of MTX. MTX is known to bind to 
dihydrofolic reductase in an almost irreversible manner, 
and would possibly interfere with calculations of 
percentage enzyme yields and with specific activity 
determinations.
Partial purification gave an approximately 50% 
yield of enzyme with an increase in specific activity
3
from 34 to 159 units of enzyme activity/mg protein x 10 ;
precipitation of contaminating protein with solid ammonium 
sulphate at 40% saturation contributed to the main loss in 
enzyme yield.
As dihydrofolic reductase migrates slowly through 
Sephadex G-100, it can be effectively separated from the 
main bulk of the enzymically inactive protein, with only a 
9% loss in enzyme yield upon its first elution from the 
column. The active fractions can be lyophilised with no 
loss in specific enzyme activity, which is approximately 
doubled upon recycling of the enzyme on the Sephadex G-100.
The purity of this enzyme preparation was calculated 
from its molecular weight (see result section 4) and the
TEE
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number of moles of MTX bound per mg protein. The latter
was estimated by titrating MTX against a known amount of
enzyme at pH 6.1 until a total inhibition of enzyme
activity was observed; under these conditions inhibition
was found to be s toichiometi;ic. If 1 mol of MTX is bound
per mol of enzyme, then the binding capacity of pure
dihydrofolic reductase would be 1/20,000 = 5 x 10"^ mol
— 8MTX per g of protein or 5 x 10 mol per mg, if the
molecular weight of dihydrofolic reductase is 20,000. The
binding capacity of the purified enzyme after recycling on
—  8the G-100 Sephadex column was determined as 4.5 x 10 mol 
MTX per mg protein, and on this basis, was estimated to be 
90% pure.
3. ASSAY OF DIHYDROFOLIC REDUCTASE ACTIVITY
Dihydrofolic reductase activity was routinely assayed 
by measuring the decrease in absorbance at 340 mu due to 
the disappearance of FH^ and NADPH. A typical assay cuvette 
contained 20|rM FH^, 20|rM NADPH, an aliquot of enzyme and 
0.1 M Tris-HCl pH 7.4 in a total volume of 2 ml. The 
reaction was started by the addition of the enzyme, and the 
initial rate of the reaction was measured on a Hilger-Watts 
spectrophotometer. One unit of enzyme activity is defined 
as the number of umol FH^ reduced per min per ml of enzyme solution 
under the assay conditions described, assuming that the
T:
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extinction coefficient at 340 for NADPH is 6,200 mol
cm  ^and for FH^ is 5,800 mol  ^ cm  ^ (Mathews, 1962b), and 
can be calculated from the following equation:-
A O ^  5.8 X  10^ ______ 1 ^  10^ X  2
5,800 (5.8 + 6.2) x 10^ Path Length ^ 1,000
3
where 5.8 x 10 ^ represents the proportion of observed
(5.8 + 6.2) X 10^
absorbency change at 340 mu due to FH^ reduction.
Protein was determined by the method of Lowry et al.
(1951), with serum albumin as the standard.
4. ELECTROPHORESIS
Electrophoresis was carried out in a Shandon Universal 
Electrophoresis apparatus with Oxoid cellulose acetate strips 
as the supporting medium. The membranes, which were 2.5 x
12.5 cm in dimension, were soaked in the electrophoresis buffer 
in the cold for at least 1 hour before use. Excess moisture 
was carefully removed by blotting the strips between tissues.
2 to 5 (il of dihydrofolic reductase extract was usually 
applied to the membranes, but if larger volumes were 
required repeated applications were undertaken. The extract 
was applied uniformly across the centre, but not quite to the 
edges of the membrane, as this resulted in a bad resolution 
of the separation. .The electrophoresis was carried out in 
the cold in 0.16 M Tris-borate buffer pH 8.5 containing
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_ 53 X  10 M EDTA at 200 volts for 4 hours. Drying out of 
the cellulose acetate strips during electrophoresis was
f
prevented by ensuring that an adequate supply of buffer 
reached the strips. This was achieved by placing the ends 
of the strips on and not between two strips of Whatman’s 
chromatography paper, the ends of which were well covered 
with buffer.
A colour reaction employing the reduction of MTT to 
its formazan was used for estimations of dihydrofolic 
reductase activity on cellulose acetate strips after 
electrophoresis. This method, first used by Gunlack et al. 
(1968) to measure dihydrofolic reductase activity in tissue 
sections, has not been used previously for determinations 
of enzyme activity on cellulose acetate strips. A similar 
system, however, was employed by Mell et al. (1968) to localise
dihydrofolic reductase activity on starch gels.
In our adaptation of the method, electrophoresis was 
carried out on about 5 p,l (containing 33 Lxg protein/p,l) 
partially purified dihydrofolic reductase (specific activity
3
154 units/mg protein x 10 ). After electrophoresis, the 
cellulose acetate strips were partially dried in a stream of 
cool air and then incubated for 20 minutes at 37°C on freshly 
made ionagar gels containing MTT and the substrates for the 
dihydrofolic reductase reaction. The gels were prepared by
eg
3
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boiling 0.1 g Oxoid No. 2 ionagar gel in 5 ml 0.1 M 
Tris-HCl buffer pH 7.4. When the agar had cooled to 
70°C, MTT (6.2 mg in 2.5 ml buffer), NADPH (3.1 mg in '
2.5 ml buffer) and finally 0.25 ml 2mM FH^ suspension 
was added. 1.8 ml aliquots of this mixture were used 
to coat one side of a glass microscope slide, and 
allowed to set at room temperature.
The amount of formazan produced as a result of the 
reduction of MTT was estimated after elution of each 
formazan band from the strip with 0.25 ml butanol and 
the absorbence at 560 m|i was measured in the eluate. The 
protein bands after electrophoresis were stained for 10 
minutes with 0.02% Ponceau S in 3% TCA. The amount of 
protein in each band was estimated by measuring the 
absorbance at 510 m|t after elution from the strip with 
0.5 ml 0.1 N NaOH and subsequent adjustment to acid pH 
with 0.02 ml 10% acetic acid.
Electrophoresis of partially purified enzyme extract 
separated the preparation into 3 bands, which produced 
formazan with MTT in the presence of NADPH, indicating that 
there were 3 systems each capable of initiating an NADPH- 
mediated hydrogen transfer reaction. Only one band was 
inhibited by the incorporation of lO”^ M MTX or the omission 
of FH^ in the gel during the assay, and represents the
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dihydrofolic reductase present in the extract. The 
other bands of formazan are thought to represent the 
activity of two NADPH-transhydrogenases. '
Parallel determinations on different volumes of 
a partially purified extract showed a linear relationship 
to exist between the amount of extract applied to the 
strip and absorbance at 560 mu due to the formazan 
(figure 3). Dihydrofolic reductase activity can, thus, 
be measured semi-quantitatively with this system.
5. RADIOACTIVE DETERMINATIONS
2 ml 0.1 M Tris-HCl pH 8.5 was added to 1.5 to
2.0 ml partially purified dihydrofolic reductase preparation, 
and boiled for 15 to 20 minutes. The supernatants containing 
the pn] MTX, obtained after centrifuging for 20 minutes at 
2,500 rev./min, were separated and used for radioactive 
determinations. 7 ml scintillator (Bray, 1960) was added to 
0.5 to 1.0 ml samples. Disintegrations per minute were 
measured using a Beckman L.S. 100 liquid scintillation 
system.
For more accurate measurements of the amount of MTX 
bound per mg enzyme, repeated extractions were carried out. 
Radioactivity could be completely removed from the 
precipitate obtained by boiling the enzyme preparation.
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This was shown by solubilising the precipitate in 
scintillator using Beckman Bio-Solv 2 after alkaline 
hydrolysis with 2N NaOH, and measuring the radioactivity 
as above.
6. MOLECULAR WEIGHT DETERMINATIONS
Molecular weights were calculated by the method 
of Whitaker (1963) using a Sephadex G-100 column (1.7 x 
153 cm) and protein standards of ^-globulin, bovine 
serum albumin, ovalbumin and ribonuclease. Elution was 
carried out at 12°C using 0.05 M Tris-HCl buffer pH 7.4 
containing 0.1 M KCl.
7. ANIMAL EXPERIMENTS - .
(I) Investigations on the effect of MTX on dihydrofolic 
reductase activity in the rat liver________________
Injections of MTX (sodium intraparenteral form) in
0.5 to 1.0 ml distilled water were given intraperitoneally
to male Sprague-Dawley rats having an initial weight of
150 to 200 g. Subsequently, the rats were anaesthetised
with ether and killed by exsanguination at various times
after the last injection of MTX. The livers were immediately
removed, together with those from two control animals of
comparable weight, and washed in a large volume of 0.9% w/v
NaCl. The livers in each experimental group were combined
(2 rats per group) and chopped finely with scissors.
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Partially purified enzyme extracts were prepared, and 
made up to a specified final volume if total activities 
were to be calculated. Specific and total activities 
of dihydrofolic reductase preparations were always 
estimated after dialysis.
%
(II) Investigations of the retention of MTX by 
dihydrofolic reductase in the rat liver
The procedure was the same as described above,
except that rats were injected intraperitoneally with
I^hJ MTX in 0.1 to 1.0 ml 0.9% w/v NaCl. Partially
purified enzyme extracts were always made from 20 g of
liver. Duplicate samples of 1.5 to 2.0 ml were taken
before and after dialysis for radioactive determinations
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C. RESULTS
1. THE EFFECT OF MTX ON DIHYDROFOLIC REDUCTASE ACTIVITY 
IN THE RAT LIVER
The large inhibition of rat liver dihydrofolic 
reductase activity observed shortly after one injection 
of 20 ug MTX is followed by a steady recovery of enzyme 
activity; the control level usually being regained within 
72 hours of injection (Figure 4). There have been varying 
reports on the recovery in vivo of dihydrofolic reductase 
from MTX inhibition. ; Sartorelli et al. (1964) and Stanley
et al. (1969) have shown an almost complete recovery in 24
hours, while Werkheiser (1962) found that 7 days after a 
lethal dose of MTX liver reductase was only 4% of the normal. 
Much confusion has resulted because of the different 
isolation procedures for the enzyme and assay of their 
activities. Werkheiser possibly observed low enzyme 
activities because his assays were carried out using folate 
as a substrate at pH 6.1, which is unlikely as a physiological 
pH. However, Stanley et al. (1969) employing an isolation
and assay procedure similar to that described here demonstrated, 
using a colorimetric assay system, that enzyme activity 
measured in situ paralleled that in isolated enzyme fractions 
when measured at pH 7.5, which showed that enzyme recoveries 
were not due to artifacts ensuing from the preparative 
procedure.
- 72 -
FIGURE 4. REœVERY OF DIHYDROFOLIC REDUCTASE ACTIVITY
IN THE RAT LIVER FOLLOWING TREATMENT WITH MTX
Rats received intraperitoneally single or repeated 
injections of 20 \ig MTX (see Methods) over varying periods 
of time. Injections were given every other day,(A = 1, 
B = 2 ,  C = 5 ,  D = 7 and E = 14 injections). The animals 
were killed at time intervals after the last injection, 
and their livers removed. Partially purified dihydrofolic 
reductase extracts were made and their specific activities 
determined (see Methods) and expressed as percentages of 
that found in non-treated rats.
Each point represents the value obtained for the 
pooled livers of two animals.
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Serial injections of 20 iig MTX produce different 
patterns of recovery from inhibition of dihydrofolic 
reductase in vivo than those following a single dose of 
the antimetabolite (Figure 4). The recovery no longer 
occurs at a.steady rate, but the maximum specific activity 
appears to be achieved within 24 hours of the last 
injection. In fact, the specific enzyme activity declines 
slightly after this.
Enzyme activity is only 30% that of the controls 72 
hours after the last of two injections of MTX. This 
implies that MTX is retained by and tightly bound to 
dihydrofolic reductase in vivo, as previously suggested 
by Hakala et al. (1961). There is, however', a most striking
recovery of dihydrofolic reductase activity after 14 
injections of MTX; a specific activity 86% that of enzyme 
extracted from uninjected animals was obtained within 24 
hours of the last dose, indicating that an adaptation by 
the liver in overcoming the inhibitory effect of the 
antimetabolite had occurred.
Recently drug resistance has been associated with 
changes in glycoprotein and glycolipid content and increased 
net negativity of the plasma membrane (Bosmann, 1971). MTX 
is negatively charged, and it would be expected that small 
changes in the net surface charge of drug-resistant cells 
could greatly affect the affinity and uptake of MTX by
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TABLE 2. TOTAL DIHYDROFOLIC REDUCTASE ACTIVITY IN CONTROL 
EXTRACT AND EXTRACTS PREPARED FROM LIVERS OF RATS 
GIVEN SERIAL INJECTIONS OF MTX
Rats were given intraperitoneally either 1 or 14 
injections of 20 ug MTX. The injections were given every 
other day and the animals killed and the livers removed 72 
hours after the last injection. Partially purified enzyme 
extracts were prepared from 5 g of tissue and made up to a 
final volume of 6 ml after dialysis. 0.05 ml of this enzyme 
solution was used for the spectrophotometric activity 
determination at 340 mp.
Each value represents the total activity obtained 
from the pooled livers of two animals.
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TABLE 2.
No. of injections
Total Activity 
(mol reduced/min/ 
0.05 ml enzyme extract)
Total Activity 
(% control)
Control: 0 0.2390
1 0.1977 83
14 0.1870 78
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these cells. That dihydrofolic reductase is only 
inhibited 50% one hour after 14 injections of MTX as 
compared to the 90% inhibition (Figure 4) observed *
in a similar time period after two such injections could 
be explained along the same lines as the above mechanism 
of drug resistance, i.e. less antifolate is taken up by 
the cells and is available for inhibition of the enzyme.
Alternatively the lack of inhibition of dihydrofolic 
reductase observed after serial injection of MTX could have 
been the result of the synthesis of elevated levels of the 
reductase. In this case, enough enzyme would have been 
present to bind all the antifolate and also to carry out 
the reduction of folic acid to its coenzymically active form 
(Hakala et al., 1961). It appeared unlikely that raised 
levels of the enzyme were present, because neither the 
specific activity nor the total activity extracted from 
any animal which had received antifolate treatment, exceeded 
that observed in the controls (Table 2). However, the 
possibility exists that MTX was still bound to the enzyme 
within 72 hours of injection, and that the total activities 
measured did not reflect the amount of enzyme present in the 
liver. Investigation into the retention of MTX by 
dihydrofolic reductase in the liver would clarify the above 
anomaly, and give indications as to whether such mechanisms 
as decreased uptake of the drug can account for the high
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enzyme activities observed.
MTX BY DIHYDROFOLIC REDUCTASE IN2. RETENTION OF 
THE RAT LIVER
The 4-amino analogues of folic acid have been shown
%
to bind in an almost irreversible manner to dihydrofolic 
reductase (Werkheiser, 1959) so that at levels of the 
inhibitor which are inadequate to cause complete inhibition, 
all the inhibitor is enzyme bound. However, diversions from 
this stoichiometric inhibition have been observed at pH 7.5 
(Mathews, 1964) and it appeared possible that the dissociation 
of the dihydrofolic reductase - MTX complex in vivo might 
attribute in part to the recovery of the reductase activity 
observed in the rat liver from inhibition by MTX.
There is a biphasic loss of I^ h] MTX from dihydrofolic 
reductase in vivo after one injection of the antifolate 
(Figure 5). Similar two-phase decreases in tritiated MTX 
content have been observed in vitro after incubations of 
whole tissue at 30°C (Kessel and Hall, 1967; Stanley et al., 
1969). With a chemotherapeutically ineffective dose, such as 
20 p,g MTX, total saturation of the enzyme with inhibitor does 
not appear to take place, as larger doses of MTX result in 
more MTX bound per mg of protein (Figure 5). However, 
approximately 20% of the total MTX can be removed from the 1 
hour extract upon dialysis, suggesting a certain amount of
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NFIGURE 5. THE EFFECT OF [ q MTX DOSE LEVEL ON ITS
RETENTION BY DIHYDROFOLIC REDUCTASE IN IHE 
RAT LIVER
Rats were injected intraperitoneally with 20 or 
200 ug pn] MTX (1 itCi) in 1.0 ml saline, and killed at 
prescribed intervals. Their livers were removed, and 
dihydrofolic reductase activity was determined in 
partially purified extracts. The specific activities 
were calculated and expressed as a percentage of that 
found in non-treated rats. Radioactivity was measured 
in 0.5 ml supernatant (see Methods) before and after 
dialysis of the dihydrofolic reductase preparations.
Each point represents the average value obtained
from 2 animals; 0 ----  0 20 ug dose before dialysis;
A  A 200 ug dose before dialysis; 0 Ô 20 ug
dose after dialysis;A A  200 ug dose after dialysis
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non-specifically bound inhibitor, which is eliminated 
in vivo within 3 to 5 hours of injection. Similar 
losses of tritiated MTX take place upon dialysis from » 
dihydrofolic reductase preparations extracted from 
animals receiving one injection of 200 \ig of MTX (Figure 
5) and after serial injections of the antimetabolite 
(Figure 6). Removal of this apparently non-specifically 
bound MTX is in these cases greater, indicating that an 
excess of MTX is present for saturation of the inhibitor- 
binding sites of the enzyme in vivo. The transport of MTX 
across the plasma membrane would not, therefore, appear to 
be affected after an extended period of treatment with MTX, 
during which time there is an apparent adaptation of the 
liver to the toxic effects of the drug.
It has been suggested that under certain conditions 
of dialysis reactivation of dihydrofolic reductase can 
occur by dissociation of the enzyme-MTX complex (Werkheiser, 
1961). Unfortunately, enzyme activities wejre not measured 
before and after dialysis, but Stanley et al. (1969), using
similar conditions of dialysis for partially purified extracts 
of rat liver dihydrofolic reductase, showed that no significant 
reactivation of the enzyme took place on removal of MTX. The 
possibility also exists that the partial loss of MTX observed 
from the extracts upon dialysis could be due to a weaker 
binding of the inhibitor to a dihydrofolic reductase if more
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FIGURE 6. MTX LEVEL IN LIVER FOLLOWING REPEATED 
INJECTIONS OF [%] MTX IN THE RAT
Animals received intraperitoneally 1 - 5  daily
3
injections of 100 [ig [Hj MTX (0.25 uCi) in 0.5 ml saline, 
and killed 1, 24 and 48 hours after the last injection.
The livers were removed and dihydrofolic reductase 
activity was determined in partially purified enzyme 
extracts. Specific enzyme activities were calculated, and 
expressed as percentages of that found in untreated rats. 
MTX (|ig/mg protein) in the liver was computed from the 
radioactivity measured in 1.0 ml supernatant (see Methods) 
after boiling of aliquots of partially purified enzyme 
extracts before and after dialysis. The number on each 
bar represents the time in hours between the last 
injection and the removal of the livers. The shading 
represents the amount of MTX (|tg/mg protein) removed by 
dialysis.
Each point represents the average value obtained 
from two animals.
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than one form of the enzyme is present in the extract.
Large initial losses of MTX from dihydrofolic 
reductase in vivo between 1 and.24 hours after one 
injection of the antifolate appear to be associated with 
corresponding increases in enzyme activity (Figure 5), 
while subsequent recovery of enzyme activity obtained 
within 24 and 72 hours of injection are clearly not 
accompanied by a similar removal of the inhibitor. This 
suggests that the recovery of dihydrofolic reductase in 
the rat liver is attributable to factors other than the 
dissociation of the enzyme-inhibitor complex. This is 
further supported by experiments with serial injections 
of MTX, where more MTX is bound and higher enzyme 
activities are observed the larger the number of injections 
(Figure 6); this situation is clearly not reconcilable with 
a ready dissociation of the dihydrofolic reductase - MTX 
complex in vivo.
Further experiments have shown that after serial 
injections of unlabelled MTX, some tritiated MTX is retained 
by the reductase from the time of one injection of pn] MTX 
to that of a similar injection given three days later (Table 
3). MTX is, therefore, taken up under these conditions and 
can combine with the dihydrofolic reductase present in the 
liver.
-  8 5  -
TABLE 3. RETENTION OF |^ h] MTX BY DIHYDROFOLIC REDUCTASE 
IN THE RAT LIVER AFTER SERIAL INJECTION OF 
UNLABELLED MTX - .
Animals received intraperitoneally 6 injections of 
200 x^g MTX/0.1 ml saline. Group (a) was given another 
injection of 200 |xg MTX/0.1 saline and a final injection 
of 2. 0* mig MTX/1.0 |xCi/1.0 ml saline, while group (b) was 
given one injection of 200 (ig MTX/0.1 uCi/0.1 ml saline 
and one injection of 2.0 mg MTX/1.0 uCi/1.0 ml saline. 
Injections were given every 3 days. The animals were 
killed and the livers removed 1, 3 and 48 hours after the 
last injection. Partially purified enzyme extracts v/ere 
made and radioactivity measured in 0.5 ml supernatant 
(see Methods) before and after dialysis. Each value was 
obtained from the mean of two samples.
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TABLE 3
Hours after last injection 
Livers removed
c.p.m./mg protein
(a) (b)
* *
84 184
1
+ +
34 53
* *
33 44
3
+ +27 38
*
12 32
48
+ +
16 24
BEFORE DIALYSIS
AFTER DIALYSIS
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If it is assumed that MTX is always present in 
excess of that required for complete saturation of all 
the dihydrofolic reductase present in the rat liver, 
then from figure 6 it could be concluded that more 
enzyme is synthesised with an increasing number of MTX 
injections as more MTX is bound per mg protein in the 
extracts. Th"e synthesis of elevated levels of 
dihydrofolic reductase appears to take place within 48 
hours of one injection of MTX, because more antifolate 
is bound per mg protein 48 hours after the injection 
than after 24 hours.
Our experiments indicate that MTX is readily taken 
up by the liver under conditions of prolonged antifolate 
therapy and combines with the dihydrofolic reductase 
present. To account for the observed recovery of enzyme 
activity from inhibition by MTX in the liver, it appeared 
possible that the synthesis of enzyme in the presence of 
MTX could involve an enzyme with altered properties, i.e. 
one with a lower affinity for MTX.
3. EVIDENCE FOR IHE EXISTENCE OF TWO DIHYDROFOLIC REDUCTASE 
SPECIES IN LI\IER EXTRACTS OF CONTROL AND MTX-TREATED RATS
Investigations on the electrophoretic separations of 
dihydrofolic reductase extracts from control and MTX-treated 
animals could be complicated by enzyme - MTX complexes 
producing different electrophoretic mobilities, which are not
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FIGURE 7. THE EFFECT OF MTX ON THE ELECTROPHORETIC
SEPARATION OF DIHYDROFOLIC REDUCTASE EXTRACTS
Rats were given a total of 44 intraperitoneal injections
r
of 20 \ig MTX. Injections were given every other day. The 
animals were killed and their livers removed, together with 
the livers from untreated control animals. Partially 
purified dihydrofolic reductase extracts were prepared.
An enzyme preparation extracted from the pooled 
livers of control animals was completely inhibited in vitro 
by the addition of 8.4 ng MTX/mg protein, as determined by 
assaying the enzyme activity at 340 m(r (see Methods).
Electrophoresis was carried out on 5 \il of the various 
extracts, and subsequently the strips were incubated in the 
presence of MTT and substrates (see Methods) and scanned on 
a Joyce-Loebl chromoscan.
The traces with the subscript ^a^ were obtained by 
scanning strips which had been incubated in the presence of 
FH^, NADPH and MTT, while those with the subscript »b* are 
of strips incubated with FH^, NADPH, MTT and 10 ^ M MTX 
(very similar traces were obtained with NADPH and MTT).
Trace 1 represents the formazan produced with a control 
extract.
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Trace 2 represents the formazan produced with a 
control extract, which had been inhibited in vitro with 
MTX before electrophoresis.
Trace 3 represents the formazan produced with an 
enzyme preparation extracted from rats that had received 
44 injections of MTX.
The numbers represent the areas under the curves as 
determined with the automatic integrator attachment.
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attributable to differences in the enzyme surface 
charges alone. It was, therefore, desirable to see 
if the in vitro addition of MTX to an extract from 
an untreated animal would have any effect on the 
electrophoretic mobilities of its components.
Determinations of the formazan-producing bands in 
the presence of NADPH, FH^ and MTT in these separations 
showed that electrophoresis completely dissociated any 
complex which MTX had with the components of the 
dihydrofolic reductase preparation, because nearly 
identical mobilities were observed in those components 
capable of mediating an NADPH - hydrogen transfer reaction 
in the control and in the completely inhibited enzyme 
(Figure 7).
Enzyme assays with MTT after electrophoresis of 
dihydrofolic reductase preparations from untreated rats 
showed the presence of 3 formazan-producing bands. The 
formation of the bands that migrated furthest from the 
origin towards the cathode, i.e. bands A and B, which 
migrated at a distance of 1.6 cm and 0.9 cm respectively, 
were not inhibited by the inclusion of lO"^ M MTX or the 
omission of FH^ from the assay gel (Figure 7), showing 
that they were not dihydrofolic reductases, but probably 
NADPH-transhydrogenase enzymes. Band B is extremely labile
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and not always present after the MTT assay in the 
presence of NADPH, and can be removed by lowering the 
pH of the partially purified dihydrofolic reductase 
extract to 5.6 before electrophoresis and subsequently 
returning the extract to pH 7.4.
After rats have been given MTX intraperitoneally 
for a period of approximately 10 days another formazan- 
producing band can be detected by assay of electrophoretic 
separations of partially purified dihydrofolic reductase 
extracts with MTT. This band is totally inhibited by the 
inclusion of 10 ^ M MTX or the omission of FH^ in the assay 
system, which indicates that there is another form of 
dihydrofolic reductase present in the rat liver, which is 
now present in sufficient quantity or activity to be 
detected by the assay system employed. It would appear that 
this enzyme form is considerably different from the 
dihydrofolic reductase detected in the control extracts, as 
it migrates in the opposite direction at pH 8.5, i.e. 
towards the anode at a distance of 0.8 cm from the origin.
Electrophoretic evidence indicates that only one form 
of dihydrofolic reductase is present in extracts from animals 
not receiving MTX treatment, but titration studies in vitro 
with MTX produce deviations from the typical Ackerman- 
Potter plots of stoichiometric inhibition in such a manner
J'
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FIGURE 8. ACKERMAN - POTTER PLOT (1949) OF THE INHIBITION 
BY MTX OF DIHYDROFOLIC REDUCTASE AT pH 7.5
A partially purified dihydrofolic reductase 
preparation was made from the pooled livers of rats which
had received no injections of MTX.
The reduction of FH^ and the oxidation of NADPH 
catalysed by the above extract was measured 
spectrophotometrically at 340 mix in the presence of a
constant amount of drug, i.e. 5 x 10 mol MTX and a
varying amount of enzyme (sp. act. 166 units/g protein) 
•(Plot A). The enzyme was incubated for 5 minutes in the 
presence of the inhibitor, and the reaction started by the 
addition of FH^.
Plot B represents theAO.D. at 340 mu, of different 
amounts of enzyme in the absence of MTX.
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as to indicate the existence of two species of the 
enzyme (Figure 8). One form of the enzyme presumably 
binds MTX so tightly that it can be titrated against  ^
a constant drug concentration, giving a straight line 
parallel to the control, while the other form exhibits 
some degree of reversibility in its binding of the 
inhibitor, and is present in so small a quantity as to 
produce the deviation from stoichiometric binding seen by 
the small curvature of the plot at low concentrations of 
the enzyme and the observed deflection of the plot from 
being parallel to the control.
4. CHROMATOGRAPHY ON SEPHADEX G-lOO OF THE TWO DIHYDROFOLIC 
REDUCTASES, AND SOME OF THEIR PROPERTIES
Chromatography on Sephadex G-lOO of partially purified 
dihydrofolic reductase extract from the pooled liver of rats, 
which had received no injections of MTX, resulted in one 
major peak (peak C) of enzyme activity being eluted from the 
column. After MTX-treatment of rats, similar Sephadex G-lOO 
chromatography of the enzyme extracted from their livers 
resolved dihydrofolic reductase activity into two peaks, the 
new peak (peak D) being eluted from the column earlier than 
the main peak of the enzyme extracted from the untreated 
animals, indicating a higher molecular weight (Figure 9).
The resolution of the two peaks of enzyme activity was
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FIGURE 9. CHROMATOGRAPHY OF DIHYDROFOLIC REDUCTASE 
EXTRACTS ON SEPHADEX G-lOO
For details of chromatography, see Methods section. 
The broken line represents protein (absorbance at 280 mu), 
and the solid line enzyme activities of dihydrofolic 
reductase extracts from the pooled livers of rats which
had received no injections of MTX (@---- 0) and 56
intraperitoneal injections of 20LLg MTX (A A).
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affected if columns of shorter length were used.
Electrophoresis experiments on lyophilised protein 
of the most enzymically active fractions from the two 
peaks separated by Sephadex G-lOO chromatography showed 
that peak C migrated 0.5 cm towards the cathode and peak D 
0.8 cm towards the anode, demonstrating that they correspond 
to the similarly labelled dihydrofolic reductases separated 
by cellulose acetate electrophoresis in the partially 
purified enzyme extracts from the liver of MTX-treated 
rats .
Sephadex G-lOO chromatography of partially purified 
enzyme extracts from animals which had received no injections 
of MTX did, however, reveal that a small amount of enzyme 
activity (approximately 10% of the total activity) is obtained 
at the same elution volume as peak D. Similar activity was 
not revealed by the MTT assay system after electrophoresis 
of comparable preparations. The proportion of the total 
activity obtained at the same elution volume as peak D 
increased from 10% after chromatography of control extracts
to 37 and 43% after chromatography of partially purified
\
enzyme extracts from animals, which had received 44 and 56 
injections respectively of 20 ug MTX. The total activity 
eluted from the Sephadex G-lOO column after chromatography 
of enzyme extract from MTX-treated and untreated rats 
remained relatively constant (Table 4).
- 99 -
TABLE 4. EFFECT OF MTX ADMINISTRATION ON DIHYDROFOLIC 
REDUCTASE ACTIVITY IN THE RAT LIVER
Rats were given intraperitoneally 0 to 56 injections 
of 20 [ig MTX; injections were given every other day. The 
animals were killed, their livers excised and pooled, and 
purified enzyme extracts prepared (see Methods) from 20 g 
of liver. Enzyme activities were estimated by measuring 
the decrease in absorbance at 340 mu, and the total activity 
calculated. The activity eluted in peaks C and D were 
estimated separately and expressed as percentages of the 
total activity eluted.
Each value was obtained for the pooled livers of two 
animals.
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Molecular weight determinations were carried out
for the two enzyme forms separated, and shown to be in
good agreement with the values previously reported by
Kaufman and Gardiner (1965) and by Bertino et al. (1965b).
For standardisation of the column 5 mg of X-globulin,
bovine serum albumin, ovalbumin and ribonuclease were
each dissolved in 2 ml buffer and eluted from the column
separately, and their elution volumes determined from the
maximum absorbance at 280 mu. X -globulin is not retarded
on the column, and its elution volume represents the void
volume. A plot of —  (V is the elution volume and V the 
 ^ V  ' oo
void volume) versus the logarithm of the molecular weight 
is presented in Figure 10. The molecular weight of 
dihydrofolic reductase represented by peak C was calculated 
to be 20,000 - 500 and that of peak D to be 24,500 - 500.
The accuracy of the determination is dependent on the volume 
of the fractions collected, because of the possibility of 
the enzyme peaks being shifted one fraction in either 
direction.
Calculation, using the double reciprocal plot of 
Lineweaver and Burk, of the Michaelis constants for FH^ of 
the two dihydrofolic reductases at pH 7.5 using NADPH as
cofactor, showed that they were approximately the same.
— 7 — 7Values of 1.6 x 10 M and 1.7 x 10 M were obtained for
the enzymes of lower and higher molecular weight respectively
-lOlA-
2 0
1-8
Dihydrofolic reductase C 
•^Dihydrofolic reductase D
1*6
Ovalbumin
T4
V Bovine serum
albumin
1 2
1-OL— ™  
4-0 4-2 50 524-84*64.4
Log mol. wt.
FIGURE 10. STANDARD CURVE FOR M OLECULAR W E IG H T  
D E T E R M IN A TIO N S  BY C H R O M A TO G R A P H /  ON G -ICO SEPHADEX  
( for  detai ls  see text)
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FIGURE 11. ESTIMATIONS OF MICHAELIS CONSTANTS FOR
DIHYDROFOLIC REDUCTASES USING THE DOUBLE 
RECIPROCAL PLOT OF LINEWEAVER AND BURK
Two rats were given on alternate days, a total of 56 
intraperitoneal injections of 20 ug MTX. They were killed 
48 hours after the last injection and purified dihydrofolic 
reductase extracts prepared from their pooled livers (see 
Methods). The enzyme from each chromatographic peak was 
recycled through the column of G-lOO Sephadex.
The initial velocity of the reaction was estimated by 
measuring the decrease in absorbance at 340 mp,/minute/ml 
enzyme solution (see Methods) in the presence of 34 [ig 
enzyme and varying concentrations of FH^, i.e. 0.5 to 20.0
_ y
X  10" M FH^. The reaction was started by the addition of 
enzyme.
The reciprocals of the velocity of the reaction and 
the concentration of FH^ were estimated and plotted for the 
enzyme eluted at peak C ( #—  1) and peak D  A).
For C: K = 1.6 x 10“*^ m
For D: K = 1.7 x 10“’’.m
CM
O
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FIGURE 12. EFFECT OF pH ON THE ACTIVITY OF DIHYDROFOLIC 
REDUCTASES ’C» AND 'D'
Purified enzyme .extracts were prepared from animals 
which had received 56 intraperitoneal injections as 
described for figure 11. Enzyme activities were estimated 
over a pH range of 4 to 8 by measuring the decrease in 
absorbance at 340 m|j, (see Methods), and the specific 
activities were calculated for the enzyme eluted at peaks 
C (#--- ê) and peak D (A A).
0.1 M citrate buffer was used over a pH range of 4 to 
7, and 0.1 M phosphate buffer between pH 6 and 8.
105
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(Figure 11).
The pH curves of the two dihydrofolic reductases 
exhibited the two optima at pH 4.5 and 7.5 usually 
observed with the mammalian enzymes when the substrates 
FH^ and NADPH are used. The lower molecular weight 
enzyme did, however, reduce FH^ more rapidly at pH 4.5 
and less rapidly at pH 7.5 than the higher molecular 
weight enzyme (Figure 12).
JJ
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D. DISCUSSION
A physiological adaptation of the rat liver to the 
folic acid antagonist MTX has been shown. Prolonged  ^
treatment with MTX of non-tumour-bearing animals results 
in the activity of dihydrofolic reductase, an important 
cellular receptor for this drug, reaching 86% that of an 
untreated animal, in spite of the large aimount of inhibitor 
that was later shown to be bound to the enzyme under 
similar conditions. In fact, the amount of MTX retained 
in the liver was estimated to be 25 times higher than 
that reported for aminopterin by Werkheiser (1962), who 
found in the soluble fraction of the mouse liver homogenate 
10 m(t mol aminopterin per g soluble protein 24 hours after 
administration of the analogue. The larger binding that vfe 
observed per g soluble protein was probably a result of 
precipitation of contaminating protein with ammonium 
sulphate.
The changes in dihydrofolic reductase activity that 
resulted as antifolate administration was prolonged could 
most readily be explained by either an increased synthesis 
of dihydrofolic reductase or a decreased uptake of MTX by 
the liver cells. However, an increase in the cellular level 
of dihydrofolic reductase cannot by itself account for the 
cellular resistance to MTX, since the drug would readily 
inactivate the enzyme if freely accessible to it. As MTX
!□
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was thought to be always in excess of the amount
required to saturate all the enzyme binding sites, it
was assumed that a mechanism other than the increased
synthesis of dihydrofolic reductase v.-ould account for
the lack of inhibition of this enzyme after the
%
administration of such a potent inhibitor to its 
activity as MTX.
Isoenzymes are a common occurrence in many 
tissues. Markert and Miller (1959) were the first to 
detect, using a colour reaction involving a tétrazolium 
salt, a larger number of lactic dehydrogenase components 
in the embryonic pig heart than in the adult heart, 
suggesting that different forms of the enzyme are 
necessary to meet a more dynamic physiological 
environment of the developing organism than would be 
required for the mature animal. Albrecht et al. (1969),
considering the different growth requirements of the 
adult and immature organisms, proposed that a low level 
of folic reductase could fulfil a shortlived physiological 
need for F in contrast to the need for dihydrofolic 
reductase, which is maintained throughout the lifespan of 
the organism, as oxidation of FH^ to FH^ is continually 
occurring during thymidylate synthesis (Friedkin, 1963).
It is of interest that we have observed no folate- 
reducing capacity of the dihydrofolic reductase isolated
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from the supernatant fraction of the rat liver homogenate. 
Presumably folate-reducing enzymes are present in the liver 
during some stage in the maturation of the animal, and 
consequently, it would be expected that the liver has the 
genetic capacity to synthesise more than one form of 
folate-reducing enzyme.
Molecular sieve chromatography showed that there 
was at least two forms of dihydrofolic reductase present 
in the liver of a normal rat. One isoenzyme is present 
in a small amount, but upon inhibition of the main bulk 
of dihydrofolic reductase present by MTX, there would 
appear to be a stimulation of its synthesis. This can be 
detected by the MTT-assay system for dihydrofolic 
reductase after electrophoresis and calculation of total 
activities recovered after chromatography on G-lOO 
Sephadex. Recently, attention has been paid to the mouse 
L1210 leukaemia made resistant to MTX, where increased 
activity of each of two forms of intracellular dihydrofolic 
reductase occurs (Harding et al., 1970). Previous studies 
on this cell line (Schrecker et al., 1962; Kashket et al., 
1965)' indicated that resistance to MTX was only accompanied 
by a raised level of dihydrofolic reductase, which was the 
only form of the enzyme found in the antifolate-sensitive 
and resistant strains.
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Indications of increased dihydrofolic reductase 
synthesis were first observed between 24 and 48 hours 
after one injection of MTX. If it concerned an enzyme
f
which was capable of utilising FH^ to some degree in 
the presence of MTX, this synthesis could account for 
the amount of dihydrofolic reductase activity observed. 
The two reductases purified from the livers of MTX- 
treated animals are similar in their affinities for 
the substrate FH^. This suggests that a mechanism 
other than a more ready reduction of FH^, or a greater 
displacement of MTX by FH^ from the enzyme, which has 
previously been shown to occur in vivo (Johns et al., 
1964a), operates in producing the observed enzyme 
activities in the presence of MTX. Unfortunately, 
turnover numbers for FH^ reduction for the two reductases 
isolated have not been calculated. Ackerman-Potter plots 
of partially purified extracts from the livers of control 
animals give evidence to support the idea that the enzyme 
synthesised in the presence of MTX shows some degree of 
reversibility in its binding of this antifolate, which 
allows it sufficient activity to catalyse the reduction 
of FHg to FH^
After prolonged administration of MTX to rats, the 
total recovery of dihydrofolic reductase activity after 
chromatography on G-lOO Sephadex of partially purified
u- Ill -
enzyme extracts from the liver was approximately the same 
as that obtained from the livers of untreated animals.
These values were taken to reflect the actual amount of 
enzyme in vivo, since chromatography on G-lOO Sephadex 
has been reported to dissociate dihydrofolic reductase 
completely from any antifolate that may be present 
(Bertino et al., 1965a). The total activity attributable 
to the low molecular weight enzyme decreases from 90% to 
57% after approximately 111 days of antifolate treatment ; 
this isoenzyme is the major form present in the extracts 
from control animals. It has been said that enzyme - MTX 
complexes are stable to the processes that normally 
catabolise enzymes in vivo, (Blakley, 1969) and it could 
be for this reason that the low molecular weight 
dihydrofolic reductase is slowly lost from the liver as 
antifolate treatment continues. The liver may act to bind 
MTX, so as effectively to reduce the concentration of the 
drug reaching the other parts of the body (a possible 
mechanism of MTX resistance observed in some tumours 
during antifolate therapy); the dihydrofolic reductase - 
MTX complex subsequently dissociates slowly and liberates 
the drug in small amounts.
The high level of dihydrofolic reductase found in a 
non-mitotic organ, such as the liver, is presumably 
associated with its function as a store for FH^-derivatives
a- 112 -
(Bertino and Hillcoat, 1968). The fact that the 
regeneration of liver is not inhibited by MTX (Brown e^ 
al. , 1965a) could be due in part to the level of the FH^- ^ 
derivatives present and to the rapid recovery of 
dihydrofolic reductase activity from inhibition that we 
have observed in the presence of this folic acid antagonist. 
It is also conceivable that the reductase in the 
regenerating tissue is predominantly of the type resistant 
to inhibition by MTX.
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